

1 **Single-Cell Transcriptomic Atlas Uncovers the Crucial**  
2 **Role of Monocyte-Derived CXCL10 and Identifies**  
3 **Viremia Biomarkers with Viral Genome Evolution**  
4 **during CHIKV Infection**

5 **Hongyang Yi<sup>1\*†</sup>, Zhenyu Yang<sup>1\*</sup>, Ruixue Dong<sup>2\*</sup>, Sumei Yang<sup>1\*</sup>, Xiaofu Wan<sup>1</sup>, Feng**  
6 **Ouyang<sup>2</sup>, Xiang Liu<sup>1</sup>, Ying Tan<sup>1</sup>, Shuhong Han<sup>1</sup>, Yuanlong Lin<sup>1</sup>, Weilong Liu<sup>1</sup>,**  
7 **Tetsuya Asakawa<sup>1</sup>, Jing Yuan<sup>1</sup>, Mingxia Zhang<sup>1†</sup>, Xiaohe Li<sup>1†</sup>, Jiayin Shen<sup>1†</sup>,**  
8 **Hongzhou Lu<sup>1†</sup>**

9 <sup>1</sup>Institute for Hepatology, National Clinical Research Centre for Infectious Diseases,  
10 The Third People's Hospital of Shenzhen and The Second Affiliated Hospital of  
11 Southern University of Science and Technology, Shenzhen 518112, China.

12 <sup>2</sup>School of Life and Health Sciences, Hainan Province Key Laboratory of One Health,  
13 Collaborative Innovation Center of Life and Health, Hainan University, Haikou, Hainan  
14 570228, China

15 \*These authors contributed equally to this work.

16 **†Correspondence:**

17 Hongyang Yi: [yihy2018@mail.sustech.edu.cn](mailto:yihy2018@mail.sustech.edu.cn);


18 Mingxia Zhang: [zmxmby@outlook.com](mailto:zmxmby@outlook.com);

19 Xiaohe Li: [13823526646@139.com](mailto:13823526646@139.com);

20 Jiayin Shen: [johnnie1111@163.com](mailto:johnnie1111@163.com);

21 Hongzhou Lu: [luhongzhou@fudan.edu.cn](mailto:luhongzhou@fudan.edu.cn).

## 22 Graphical abstract



23

## 24 Highlights

- 25 ● CXCL10, which is transcriptionally driven by pre-macrophages and monocytes,
- 26 exerts a crucial role in the innate immune response during CHIKV infection.
- 27 ● CHIKV induces elevated proportions of naive CD4<sup>+</sup> T and CD8<sup>+</sup> T cells, with CD8<sup>+</sup>
- 28 T cell proportions declining during convalescence while CD4<sup>+</sup> T cell proportions
- 29 remain persistently elevated.
- 30 ● The interferon pathway is activated in all PBMCs and plays a key role in inhibiting
- 31 viral replication, while the differentiation, killing and NF-κB pathway function of
- 32 NK cells were inhibited.

- 33 ● Plasma mRNA levels of TAP1, ISG15, CMPK2, GBP4, OTOF and SIGLEC1,  
34 along with CXCL10 cytokine, were identified as biomarkers associated with the  
35 severity of CHIKV viremia.
- 36 ● Two genomically distinct CHIKV strains (ECSA) were identified, which harbor  
37 key mutations of E1-A226V, E2-L210Q and E2-I211T, besides specific mutations  
38 of C-T143A, E1-R157K and E2-Q282K.

## 39 **Abstract**

40 Widespread local transmission of Chikungunya virus (CHIKV) in China poses a  
41 severe challenge to public health. However, to date, the immunological characteristics  
42 of peripheral blood mononuclear cells (PBMCs) in CHIKV-infected individuals have  
43 not been characterized in a systematic manner, and specific plasma biomarkers for  
44 clinical diagnosis remain lacking. Herein, we applied single-cell RNA sequencing  
45 (scRNA-seq) to construct a high-resolution transcriptomic landscape of PBMCs from  
46 CHIKV-infected individuals for the first time. In combination with a 120-plex plasma  
47 cytokine assay and next-generation sequencing (NGS) of plasma RNA, we multi-  
48 dimensionally characterized the immunological features of CHIKV-infected patients  
49 and identified potential plasma biomarkers. Our analyses unveiled extensive activation  
50 of innate immune pathways marked by significant upregulation of interferon (IFN)-  
51 related signaling pathways in CHIKV-infected individuals. Notably, we identified  
52 CXCL10, a factor transcriptionally dominated by monocytes and pre-macrophage  
53 subsets, as a potential key immune mediator, and found that plasma host mRNAs  
54 including TAP1 and CMPK2, etc., could serve as potential auxiliary biomarkers for  
55 clinical diagnosis. Phylogenetic analysis demonstrated that the CHIKV strain  
56 circulating in Shenzhen belongs to the East/Central/South African (ECSA) genotype  
57 and harbors specific mutations of C-T143A, E2-Q282K and E1-R157K. Collectively,  
58 this study systematically depicts the peripheral blood immune responses of CHIKV  
59 patients from the perspectives of single-cell transcriptome, plasma host transcriptome  
60 and cytokines, providing valuable insights into the immunopathogenesis of CHIKV  
61 infection, the development of diagnostic biomarkers and the design of targeted  
62 therapeutic strategies.

63 **Keywords:** scRNA-seq; CHIKV; PBMCs; Pre-macrophage; CXCL10; ECSA;  
64 Cytokines.

## 65 Introduction

66 Chikungunya fever (CHIKF) is an acute mosquito-borne infectious disease caused  
67 by the CHIKV, characterized by high infectivity and rapid spread<sup>1</sup>. In recent years, the  
68 virus has become endemic in over 100 countries spanning Africa, the Americas, and  
69 Asia, with cumulative reported cases exceeding ten million and approximately 2.8  
70 billion people at risk of infection, posing ongoing pressures on local public health and  
71 socioeconomic systems<sup>2</sup>. Of particular concern is that imported cases in Guangdong  
72 Province, China, have already triggered local transmission chains and show a potential  
73 trend of spreading to neighboring provinces<sup>3</sup>. Currently, there are no specific antiviral  
74 drugs globally targeting the CHIKV, nor any widely approved vaccines. Although the  
75 Ixchiq vaccine received approval from the US Food and Drug Administration (FDA) in  
76 2023, its long-term protective efficacy and immune durability still require further  
77 validation in real-world settings<sup>4</sup>. Against this backdrop, elucidating the  
78 immunopathological mechanisms of the CHIKV have become critical challenges in the  
79 global public health domain.

80 The accelerated spread of the epidemic is fundamentally driven by the synergistic  
81 effects of viral evolution and environmental factors. Over the past few decades, *Aedes*  
82 *albopictus*, originally from Asia with a preference for animal blood-feeding, has  
83 gradually replaced *Aedes aegypti* as the primary vector for the CHIKV<sup>5</sup>. A key  
84 mechanism underlying this vector shift is the amino acid substitution at position 226 of  
85 the CHIKV E1 protein, where alanine is replaced by valine (E1-A226V)<sup>6</sup>. Studies have  
86 shown that, compared with *Aedes aegypti*, *Aedes albopictus* exhibits stronger  
87 ecological adaptability, with a distribution range extending into higher-latitude  
88 temperate regions and a higher susceptibility to the CHIKV, thereby significantly  
89 enhancing the transmission potential of the virus<sup>7</sup>. Concurrently, the virus itself has  
90 undergone adaptive evolution under the selective pressure of *Aedes albopictus*<sup>8</sup>. For  
91 instance, the E2-L210Q mutation further improves the transmission capacity and  
92 adaptability of CHIKV<sup>9</sup>, while the E2-I211T mutation can partially relieve the epistatic

93 suppression effect on the E1-A226V mutation<sup>10</sup>. Phylogenetic analyses reveal that the  
94 CHIKV can be divided into four major geographic lineages: the West African, East-  
95 Central-South African (ECSA), ECSA-diverged or Indian Ocean Lineage (IOL) and  
96 Asian lineage<sup>11</sup>. The strains that have sporadically appeared in China previously mostly  
97 belong to the Asian type or the IOL type<sup>12</sup>.

98 In terms of clinical manifestations, patients often present with acute fever, rash,  
99 and symmetric severe polyarthralgia, typically affecting the wrists, ankles, and knees.  
100 Notably, approximately 50% of infected individuals may develop chronic arthritis, with  
101 symptoms persisting for several years, severely impacting their quality of life and  
102 socioeconomic functioning<sup>13</sup>. Research shows that the CHIKV, has a short incubation  
103 period, and the acute phase is characterized by high-level viremia. During this stage,  
104 monocytes are extensively recruited to the sites of infection, differentiating into  
105 macrophages and releasing large quantities of pro-inflammatory factors. Meanwhile,  
106 activated T cells - particularly CD4<sup>+</sup> and CD8<sup>+</sup> subsets - participate in viral clearance  
107 and tissue damage through effector secretion and cytotoxic activities<sup>14</sup>. At the molecular  
108 level, type I and type II interferon pathways are rapidly activated, inducing the  
109 expression of hundreds of interferon-stimulated genes (ISGs) and establishing a broad  
110 antiviral state<sup>15</sup>. Simultaneously, key signaling pathways such as NF-κB are triggered  
111 by viral RNA, promoting the release of pro-inflammatory cytokines like IL-1β, IL-6,  
112 and TNF-α, as well as chemokines such as MCP-1 and CXCL10<sup>16,17</sup>. Notably, previous  
113 studies have indicated that the severity of CHIKV disease is closely associated with  
114 high serum levels of chemokines such as CXCL10<sup>18</sup>. These mediators not only further  
115 recruit immune cells, forming inflammatory infiltrates, but also directly increase  
116 vascular permeability, cause tissue edema, and induce pain sensitization, thereby  
117 collectively mediating the acute-phase rash and severe arthralgia, while also laying the  
118 foundation for the pathological progression of chronic arthritis<sup>19</sup>.

119 Although previous studies have preliminarily uncovered the immunopathological  
120 features of CHIKF, a systematic understanding of the dynamic changes in peripheral  
121 immune cells throughout the entire disease course remains to be elucidated. Specifically,

122 the quantitative distribution, phenotypic characteristics, subset composition, and  
123 functional states of key immune populations, such as T cells, B cells, monocytes, and  
124 NK cells - across different disease stages have not been clearly defined. While  
125 conventional bulk RNA sequencing has provided valuable insights into systemic  
126 immune responses, its technical limitation in resolving cellular heterogeneity obscures  
127 critical cell type-specific information<sup>20</sup>. This methodological bottleneck is particularly  
128 pronounced in CHIKV research, as the differential responses of immune cell subsets  
129 are key determinants of viral clearance efficiency, disease progression trajectory, and  
130 the development of chronic joint symptoms. To overcome this limitation, we performed  
131 scRNA-seq analysis on peripheral blood mononuclear cells (PBMCs) from a well-  
132 defined clinical cohort. The cohort design included healthy controls, patients with acute  
133 - and convalescent-stage CHIKF, and a specifically incorporated older individual at  
134 higher risk of severe disease. Through this strategy, we achieved an unbiased dissection  
135 of the immune landscape during infection at single-cell resolution, precisely identifying  
136 various cell subsets, systematically characterizing their transcriptional dynamics across  
137 disease stages and age groups and thereby revealing the dysregulated cell type-specific  
138 signaling networks in CHIKV infection. To further validate these transcriptomic  
139 findings at the protein level, we employed high-throughput multiplex cytokine assays  
140 to quantitatively profile 120 key inflammatory mediators and chemokines in plasma.  
141 This approach not only provided proteomic corroboration of the scRNA-seq data but  
142 also uncovered functional insights at the post-transcriptional regulatory level.  
143 Leveraging its high sensitivity and multi-parameter simultaneous analysis capabilities,  
144 we were able to construct a comprehensive regulatory axis from gene expression to  
145 protein secretion, offering multi-dimensional experimental evidence for understanding  
146 the immune response mechanisms in CHIKF.

147 In summary, this study integrated single-cell transcriptomics, plasma proteomics,  
148 and viral evolutionary analysis to construct a framework of the host immune responses  
149 and genetic evolution of the CHIKV. We systematically characterized viral lineage  
150 features and simultaneously deciphered the specific immune cell and molecular events

151 triggered by infection, thereby revealing potential coupling relationships between viral  
152 variation and clinical immunophenotypes. This work establishes a multi-omics  
153 theoretical foundation for future precision prevention and treatment strategies.

## 154 **Results**

### 155 **The scRNA-seq atlas of PBMCs from CHIKV-infected patients and healthy** 156 **donors**

157 To comprehensively characterize the peripheral immune response to CHIKV  
158 infection, we performed scRNA-seq on PBMCs isolated from 6 samples with CHIKV  
159 infection, including 3 acute-phase infection (A-infection), 2 convalescent-phase  
160 infection (C-infection) and 1 elderly A-infection, as well as 3 healthy donors (**Fig 1a**),  
161 and also performed multi-cytokine detection and RNA sequencing for the patients'  
162 plasma. The demographics and clinical features of the patient cohort and healthy donors  
163 are summarized in **Table 1**. Samples were collected from patients at 3 to 8 days post  
164 symptom onset. Notably, lymphocyte counts in all patients were below the normal  
165 reference range. This observation may be attributable to direct viral invasion and  
166 destruction of lymphocytes, or alternatively, the massive mobilization of lymphocytes  
167 to infected sites (e.g., the ankle joint, rash area) for participation in local immune  
168 responses. Following stringent quality control (**Fig S1a**), we obtained transcriptome  
169 data for a total of 81296 high-quality cells. Unsupervised clustering analysis identified  
170 12 distinct cell clusters, which were visualized using t-distributed stochastic neighbor  
171 embedding (t-SNE) (**Fig 1b, Fig S1b**). Each cluster was annotated according to well-  
172 established lineage-specific marker genes (**Fig 1c-d**). Cluster 1 (CD3D<sup>+</sup>/CD3E<sup>+</sup>/CD3G<sup>+</sup>)  
173 was identified as CD4<sup>+</sup> T cells, and Cluster 2 (LEF1<sup>+</sup>/TCF7<sup>+</sup>/CCR7<sup>+</sup>) was annotated as  
174 naive CD4<sup>+</sup> T cells. Cluster 3, characterized by expression of CD8A, CD8B, CD3D,  
175 CD3E, and CD3G, was defined as CD8<sup>+</sup> T cells. Cluster 4, which also expressed CCR7,  
176 LEF1, and TCF7, was classified as naive CD8<sup>+</sup> T cells. Cluster 5, expressing MS4A1,  
177 CD79A, and CD79B, was identified as B cells. Cluster 6 (plasma B cells) exhibited  
178 high expression of JCHAIN, IGHG1, and IGHG2. Cluster 7 (monocytes) was marked

179 by VCAN, CD14, S100A8, and S100A9. Notably, we defined a cell cluster (Cluster 8)  
180 by its high co-expression of defining monocyte/macrophage markers (CSF1R,  
181 FCGR3A/CD16, CX3CR1, FCGR1A/CD64, CCR2). The combined evidence from its  
182 distinct transcriptomic signature and trajectory inference, which localized it to an  
183 intermediate state between monocytes and macrophages, provided compelling evidence  
184 to annotate it as “Pre-macrophage”<sup>21-23</sup>. Cluster 9 was annotated as conventional  
185 dendritic cells (cDCs) based on expression of CD1C, FCER1A, and CLEC10A. Cluster  
186 10 was classified as plasmacytoid dendritic cells (pDCs) according to expression of  
187 LILRA4, FCER1A, and IRF7. Cluster 11, expressing KLRF1, NCAM1, and NCR1,  
188 was identified as NK cells. A small platelet population (Cluster 12) was defined by  
189 PPBP, PF4, and GP9 expression. These well-defined subsets were subsequently used to  
190 investigate cell-type-specific antiviral responses and immune dysregulation during  
191 CHIKV infection.

## 192 **scRNA-seq reveals immune perturbations in acute CHIKV infection**

193 Given that the acute phase of CHIKV infection represents a critical window for  
194 virus-host immune interaction, where cellular states closely resemble the “primary  
195 response” post-viral infection and can clearly reflect immune cell changes directly  
196 induced by the virus. However, the specific roles of viral replication and host immune  
197 responses in CHIKV infection have not been fully elucidated. Therefore, this study  
198 focused on dissecting the immunological characteristics of PBMCs during the acute  
199 infection phase using scRNA-seq. To characterize the functional states and dynamic  
200 changes of different cell populations in PBMCs from CHIKV-infected patients, we first  
201 performed tSNE dimensionality reduction analysis on PBMCs from the A-infection  
202 group and the normal group (control). The results showed that the proportions of  
203 monocytes, pre-macrophages, naive CD4<sup>+</sup> T cells, and naive CD8<sup>+</sup> T cells were  
204 increased in patients with acute infection, whereas the proportions of NK cells, CD8<sup>+</sup> T  
205 cells, and platelets were markedly decreased (**Fig 2a-b & Fig S2a**). These findings  
206 indicate that innate and adaptive immune responses exert complex regulatory effects  
207 during the acute phase of CHIKV infection.

208 Subsequently, we analyzed the transcriptomic data of 12 cell populations and  
209 found that monocytes and pre-macrophages had the largest number of differentially  
210 expressed genes (DEGs). Additionally, many interferon-induced protein (IFIT) genes  
211 were significantly upregulated across all cell populations (**Fig 2c-d**). Further Gene  
212 Ontology (GO) enrichment analysis of all cells revealed that the “*regulation type*  
213 *interferon production*” pathway was significantly activated, suggesting a crucial role of  
214 the interferon pathway in responding to acute CHIKV infection, which is consistent  
215 with previous studies<sup>24</sup>. Besides, pathways related to innate immune response,  
216 lymphocyte activation, and negative regulation of viral replication were also activated,  
217 indicating that the host is actively responding to exogenous viral invasion, although the  
218 underlying mechanisms require further investigation (**Fig 2d**). In contrast, pathways  
219 such as ribosome biogenesis, translation, and nucleocytoplasmic transport were  
220 significantly suppressed in the acute stage of CHIKV infection (**Fig S2b**). This may be  
221 attributed to the fact that viral genome replication and protein synthesis rely on the  
222 host’s ribosomal and translational systems. The host cells limit the replication and  
223 spread of the virus within immune cells at the cost of “sacrificing part of their own  
224 protein synthesis”.

225 The innate immune system serves as the first line of defense against CHIKV  
226 infection, with core functions including early viral recognition, initiation of rapid  
227 antiviral responses, restriction of viral replication and dissemination, as well as bridging  
228 the adaptive immune response - processes that are critical for controlling acute infection  
229 and preventing chronic pathological damage. Among innate immune mediators, type I  
230 interferons are central effector molecules in counteracting CHIKV infection<sup>25</sup>. To  
231 further evaluate the significance of interferon and inflammatory immune responses  
232 during CHIKV infection, we analyzed the expression levels of key innate immune  
233 pathways (defined by GO biological process terms) in the A-infection group. The  
234 results demonstrated that acute inflammatory responses, TNF $\alpha$  and TNF $\beta$  response,  
235 type I interferon responses, and type II interferon responses were significantly  
236 upregulated in most cell clusters, with particularly pronounced elevation in monocytes

237 and pre-macrophages (**Fig 2e & Fig S2c**). This suggests that monocytes and pre-  
238 macrophages may act as crucial sources of innate immunity and inflammatory storms  
239 during the acute phase of CHIKV infection. In contrast, type III interferon responses  
240 showed no obvious overall activation and were even slightly downregulated in some  
241 cell clusters (**Fig S2c**). IFN- $\alpha/\beta$  can bind to interferon receptors (IFNAR1/2) on the  
242 surface of host cells, thereby activating the JAK-STAT signaling pathway and inducing  
243 the expression of hundreds of interferon-stimulated genes (ISGs)<sup>26</sup>. To further confirm  
244 the critical role of the interferon pathway in CHIKV infection, we assessed the  
245 expression levels of ISGs in key cell clusters. The results showed that ISGs expression  
246 was significantly upregulated across all cell clusters, with the most striking increase  
247 observed in monocytes and pre-macrophages (**Fig 2f**). These data further validate the  
248 central role of these two cell populations in mediating innate immune responses during  
249 the acute stage of CHIKV infection.

250 Dysregulated intercellular communication is a critical driver of exacerbated  
251 inflammation and tissue damage during viral infections. Therefore, we utilized  
252 CellChat to analyze 70 pivotal signaling pathways, with a focus on identifying cell  
253 populations that act as major senders (outgoing signaling) or receivers (incoming  
254 signaling) of intercellular cues. Following CHIKV infection, pre-macrophages and  
255 dendritic cells emerged as central hubs in the intercellular communication network,  
256 functioning as both predominant outgoing and incoming signaling cell populations.  
257 This dual role highlights their core position in coordinating immune responses during  
258 CHIKV infection. Post-infection, the outgoing signals of multiple pathways were  
259 significantly enhanced, including CALECTIN, PECAM2, ANNEXIN, LAIR1, TNF,  
260 CXCL (predominantly derived from pre-macrophages), CCL, TRAIL, and SN  
261 pathways. Notably, CD8<sup>+</sup> T cells in the infected group secreted CD69 signals - this may  
262 be a compensatory activation response of CD8<sup>+</sup> T cells to viral infection, despite their  
263 impaired proliferation and differentiation, reflecting an attempt to maintain partial  
264 immune surveillance function. In monocytes and pre-macrophages, the major incoming  
265 signaling pathways post-infection included CALECTIN, LAIR1, TRAIL, CCL, TNF,

266 and ANNEXIN, which may be involved in activating these cells to initiate antiviral  
267 responses. For NK cells, the key incoming signaling pathways were SN, PECAM2,  
268 VISFATIN, ADGRG, and NCAM, which may regulate NK cell activation, cytotoxicity,  
269 or differentiation during CHIKV infection (**Fig 2g-h & Fig S2c**).

270 These results collectively confirm the crucial role of type I and type II interferon  
271 responses during acute CHIKV infection, as well as the roles of monocytes/pre-  
272 macrophages as key sources of innate immunity and hubs of intercellular  
273 communication, and initially clarify the immunological characteristics of acute CHIKV  
274 infection.

### 275 **CXCL10 exerts a crucial role in monocytes and pre-macrophages during acute** 276 **infection**

277 Our findings demonstrated a significant increase in the proportions of monocytes  
278 (31.5%) and pre-macrophages (10.7%) in the acute phase of CHIKV infection,  
279 compared to the normal group (22.3% for monocytes and 2.4% for pre-macrophages,  
280 respectively). Notably, the proportion of pre-macrophages exhibited an exceptionally  
281 abnormal elevation, reaching a 4.5-fold increase (**Fig 2a-b**). This observation suggests  
282 that these two cell populations play crucial roles in CHIKV immunity. Previous studies  
283 have indicated that monocytes and macrophages are more susceptible to CHIKV  
284 infection and serve as the primary infiltrating cell types at the infection site<sup>27</sup>.

285 To dissect the specific immune responses of monocytes and pre-macrophages  
286 during the acute stage of CHIKV infection, we performed sub-clustering analysis on  
287 these two cell populations. Based on their gene expression patterns, they were  
288 categorized into 6 major subclusters (**Fig 3a**). We observed that the proportions of  
289 Cluster 1, 2 and 5 were significantly reduced in the A-infection group, while the  
290 proportions of Cluster 3, 4 and 6 were markedly increased (**Fig 3b**). Among these  
291 subclusters, Cluster 3 was primarily composed of pre-macrophages and showed the  
292 most prominent increase in proportion (**Fig 3c**). Genes highly expressed in Cluster 3  
293 included FCGR3A, HES4, SETBP1, and CDKN1C. Among these, FCGR3A mediates  
294 the phagocytic capacity of monocytes/macrophages and antibody-dependent cell-

295 mediated cytotoxicity (ADCC), thereby enhancing the ability to eliminate virus-  
296 infected target cells<sup>28</sup>. Subsequently, we analyzed the A-infection group at the  
297 transcriptomic level and found that CHIKV infection induced dramatic changes in the  
298 transcriptomic landscapes of monocytes and pre-macrophages (**Fig S3a, S3d**). KEGG  
299 enrichment analysis demonstrated that the NOD-like receptor signaling pathway and  
300 Toll-like receptor signaling pathway were preferentially activated in both cell  
301 populations (**Fig S3b, S3e**). This indicates that monocytes and pre-macrophages  
302 actively respond to viral invasion and serve a critical function in resisting CHIKV  
303 infection and regulating inflammation. Interestingly, we detected a significant  
304 upregulation in the transcriptional levels of the pro-inflammatory cytokine CXCL10 in  
305 both cell populations (**Fig S3a, S3d**), suggesting that CXCL10 may act as a key  
306 mediator in viral immunity and inflammatory responses during infection. Therefore, we  
307 further analyzed the specific expression of CXCL10 across the 6 cell clusters. The  
308 results showed that the proportion of cells with high CXCL10 expression increased  
309 most significantly in Cluster 3 (pre-macrophages) of A-infection group (**Fig 3e**). To  
310 further elucidate the role of CXCL10 in combating CHIKV infection, we isolated cell  
311 populations with high CXCL10 expression from monocytes and pre-macrophages in  
312 the A-infection group and compared them with those with low CXCL10 expression  
313 (**Fig S3g-S3h**). Enrichment analysis of DEGs revealed that cells with high CXCL10  
314 expression responded more actively to CHIKV infection, as pathways such as “*defense*  
315 *response to virus*” and “*regulation of innate immune response*” were preferentially  
316 activated. This further confirms the pivotal function of CXCL10 in CHIKV immunity.

317 To investigate the differentiation trajectory between different subsets of  
318 monocytes and pre-macrophages during the acute stage of CHIKV infection, we  
319 performed pseudotime analysis using Monocle2 and generated pseudotime trajectory  
320 plots to determine the relationship between cell differentiation trajectories and disease  
321 states. The analysis revealed that CHIKV infection promotes the differentiation of  
322 monocytes into pre-macrophages (Cluster 3) (**Fig 3h-i**). We mapped the CXCL10-high  
323 cell population onto the trajectory plot and found that CXCL10-high cells were mostly

324 located at the terminal differentiation position, which largely corresponded to Cluster 3  
325 (pre-macrophages) (**Fig 3j**). This indicates that the CXCL10-high cell population is  
326 likely crucial in responding to CHIKV infection, and may play an essential role in  
327 promoting the conversion of monocytes to pre-macrophages, or facilitating the  
328 migration of pre-macrophages to infection sites and exerting immune functions at local  
329 infection foci.

330 To further explore the differentiation characteristics of monocytes and pre-  
331 macrophages in CHIKV-infected patients, we constructed a gene expression heatmap  
332 based on the pseudotime trajectory. Genes were categorized into two clusters according  
333 to the pseudotime trajectory: Cluster 1 represented genes upregulated in the late  
334 differentiation stage, while Cluster 2 represented genes downregulated in the late  
335 differentiation stage (**Fig 3k**). Functional annotation of Cluster 1-related genes showed  
336 that many of these genes are directly or indirectly associated with the migratory  
337 capacity of monocytes/macrophages. For example, the Sell gene encodes L-selectin,  
338 which mediates the rolling adhesion of monocytes to vascular endothelial cells and  
339 serves as a critical initial step in migration<sup>29</sup>. CD53, a tetraspanin protein, regulates  
340 immune cell adhesion and migration<sup>30</sup>. SLAMF7 is upregulated following macrophage  
341 activation and enhances cell migration and infiltration<sup>31,32</sup>. Prostaglandins synthesized  
342 by PTGS2 (cyclooxygenase-2) act as important chemotactic signals for macrophage  
343 migration<sup>33</sup>. Both JUN (a member of the AP-1 family) and ATF3 are transcription  
344 factors that directly regulate the expression of migration-related genes (e.g., adhesion  
345 molecules and chemokine receptors)<sup>34,35</sup> (**Fig 3k & Fig S3k-o**). Collectively, these  
346 results indicate that CHIKV infection induces the differentiation of monocytes into pre-  
347 macrophages and their subsequent infiltration into the infection site, whereby CXCL10  
348 may act as a key mediator in this process.

### 349 **Immune characterization of NK and CD8<sup>+</sup> T cells during the acute infection**

350 In the acute stage of CHIKV infection, distinct from monocytes and pre-  
351 macrophages, the proportions of NK cells (6.6%) and CD8<sup>+</sup> T cells (11.4%) were  
352 significantly decreased compared to the normal group (17% for NK cells and 24.3% for

353 CD8<sup>+</sup> T cells, respectively) (**Fig 2a-b**). This abnormal phenomenon may be closely  
354 associated with immune dysfunction following CHIKV infection. Although NK cell-  
355 mediated innate immunity and CD8<sup>+</sup> T cell-mediated adaptive immunity play important  
356 part in CHIKV infection<sup>36</sup>, the functional impacts of these cells on the progression of  
357 CHIKV disease remain unclear. Given this, we conducted a detailed analysis of the  
358 immunological characteristics of NK cells and CD8<sup>+</sup> T cells post-infection.

359 NK cells are present in the inflammatory microenvironment of many viral  
360 infections, including CHIKV, and are among the earliest effector cells to respond to  
361 viral invasion. They exert their functions by producing interferon- $\gamma$  (IFN- $\gamma$ ), secreting  
362 cytokines, and exerting cytotoxic effects<sup>37</sup>. Despite this, their function during CHIKV  
363 infection remains undefined. Previous studies have suggested that NK cells can control  
364 viral infection through specific expansion during the acute phase of CHIKV infection<sup>38</sup>,  
365 but our results showed the opposite trend. To address this discrepancy, we performed  
366 sub-clustering analysis on NK cells, which were classified into 3 major subclusters  
367 based on gene expression patterns: Cluster 1 consisted of naive NK cells, while Clusters  
368 2 and 3 belonged to effector NK cells. The results revealed a significant increase in the  
369 proportion of naive NK cells in the A-infection group (**Fig 4a-b**), implying that the  
370 differentiation and proliferation capacities of NK cells may be affected by CHIKV  
371 infection. We further used CytoTRACE to evaluate the differentiation potential of  
372 different single-cell subclusters. As shown in **Fig 4c and Fig S4a**, Clusters 1, 2, and 3  
373 in the infection group exhibited higher CytoTRACE scores than those in the normal  
374 group - an indicator of superior differentiation potential. This finding further confirms  
375 that CHIKV infection can inhibit the proliferation and differentiation of NK cells. DEG  
376 analysis of terminally differentiated infected NK cell Cluster 3 identified significant  
377 enrichment of viral defense-related terms (**Fig 4d & S4b-c**). To better construct the  
378 differentiation trajectory of NK cells and clarify their dynamic changes during  
379 development, differentiation, or CHIKV infection, we performed pseudotime analysis  
380 on NK cells from the normal group and A-infection group. The results showed that,  
381 compared to the differentiation trajectory of NK cells in the normal group (fate2), NK

382 cells in the A-infection group differentiated in the opposite direction (fate1) (**Fig 4e-f**).  
383 This indicates that although NK cells from both the normal and A-infection groups can  
384 be divided into three similar subclusters, the gene expression patterns of NK cells have  
385 undergone fundamental changes post-infection. Specifically, the fate of NK cells  
386 underwent a programmed shift at the Branch3 decision point (**Fig 4e-f**). We therefore  
387 analyzed the Branch3 fate decision point and found that fate1-related genes were  
388 closely associated with the inhibition of viral replication (**Fig 4g-h**). This suggests that  
389 NK cells initiate an innate immune response against the virus in the acute stage of  
390 CHIKV infection, which is consistent with relevant reports<sup>37</sup>. Notably, fate2-related  
391 genes were enriched in pathways such as “*response to tumor necrosis factor (TNF)*”  
392 (**Fig 4i**), indicating that the TNF-mediated innate immune pathway of NK cells is  
393 inhibited in the acute stage of CHIKV infection—a striking observation. In addition, the  
394 upregulation of genes such as CD69 (a marker of NK cell activation) and GNLY (a  
395 marker of NK cell effector function) in fate2 implies that the partial activation status  
396 and cytotoxic function of NK cells are suppressed in the A-infection group (**Fig 4j**). In  
397 summary, these results demonstrate that although NK cells play an important role in  
398 antiviral immunity following CHIKV infection, the CHIKV virus can partially inhibit  
399 the differentiation of NK cells into effector cells and impair some of their functions -  
400 such as suppressing the activation of the TNF pathway in NK cells.

401 A previous study reported that lymphopenia was a major laboratory feature in  
402 patients with acute chikungunya fever during the Reunion Island outbreak<sup>39</sup>. Our  
403 research further confirmed that the reduced lymphocytes are primarily CD8<sup>+</sup> T  
404 lymphocytes. However, the role of CD8<sup>+</sup> T cells in the pathogenesis of CHIKV remains  
405 poorly understood. Our results showed that although the overall proportion of CD8<sup>+</sup> T  
406 cells was significantly downregulated post-infection, the proportion of naive CD8<sup>+</sup> T  
407 cells in the A-infection group (7.1%) was indeed upregulated compared to the normal  
408 group (4.9%) (**Fig 2a-b**). Based on gene expression patterns, CD8<sup>+</sup> T cells (including  
409 naive CD8<sup>+</sup> T cells) were classified into 6 major subclusters, with Cluster 1 identified  
410 as naive CD8<sup>+</sup> T cells and its proportion increased 2.3-fold after infection (**Fig 4k-i &**

411 **S4d-e)**. DEG analysis revealed that Naive CD8<sup>+</sup> T cells (C1) in the A-infection group  
412 had already initiated a robust immune response to CHIKV infection (**Fig S4f-h**).  
413 Pseudotime analysis revealed that the proportion of cells at early pseudotime stages in  
414 the A-infection group was significantly increased compared with the normal group  
415 regarding cellular differentiation trajectories (**Fig 4m-n**). Subsequently, we constructed  
416 a pseudotime trajectory heatmap based on gene expression patterns. Genes associated  
417 with Cluster 2 were significantly upregulated at late pseudotime stages, and enrichment  
418 analysis identified significant enrichment of immune activation-related terms (**Fig 4p**).  
419 In contrast, genes related to Cluster 1 were markedly upregulated at early pseudotime  
420 stages, and enrichment analysis of these genes showed enrichment for both cytoplasmic  
421 translation and ribosomal biogenesis terms (**Fig 4q**). CytoTRACE analysis was  
422 performed to assess the differentiation potential of distinct subsets in the A-infection  
423 and normal groups, which revealed that the differentiation potential of CD8<sup>+</sup> T cells  
424 was not inhibited by CHIKV infection (**Fig S4i**). This finding suggests that the  
425 abnormally increased naive CD8<sup>+</sup> T cells may result from elevated emergency thymic  
426 output or proliferation of the peripheral resting naive pool. Interestingly, we found that  
427 KLF7 - a gene highly expressed at the early stage of pseudotime that promotes the  
428 survival and proliferation of naive T cells - was conversely downregulated in the A-  
429 infection group (**Fig S4j**), implying that CHIKV infection does not enhance the survival  
430 and proliferation of naive T cells. Subsequently, we annotated naive CD8<sup>+</sup> T cells (C1)  
431 using the marker panel for newly thymus-emigrated cells (PECAM1<sup>+</sup>PTPRC<sup>+</sup>CCR7<sup>+</sup>),  
432 and found that the expression of this marker panel was rather lower in the A-infection  
433 group (**Fig S4k**), which indicates impaired thymic output capacity. Therefore, the  
434 abnormal increase in naive CD8<sup>+</sup> T cells following CHIKV infection remains  
435 unexplainable based on the current experimental evidence. In summary, we confirmed  
436 that CHIKV acute infection-induced lymphopenia is primarily attributable to the  
437 reduction in CD8<sup>+</sup> T lymphocytes, while the proportion of naive CD8<sup>+</sup> T lymphocytes  
438 is significantly elevated, and the underlying mechanism requires further investigation.

439 **Elevated plasma CXCL10 drives innate-adaptive immune crosstalk during**  
440 **CHIKV infection**

441 After comprehensively delineating the intricate heterogeneity of immune cells and  
442 dynamic transcriptional programs at single-cell resolution, we sought to further  
443 determine whether these cell-intrinsic alterations are reflected in the systemic  
444 circulation - a critical link between local immune responses and systemic  
445 pathophysiological changes during infection. To address this pivotal question, we  
446 systematically profiled the plasma concentrations of 120 functionally relevant proteins  
447 via the high-sensitivity Human Cytokine Array Q2000 platform. The analysis was  
448 performed on clinical samples specifically collected from individuals during the acute  
449 phase of viral infection, ensuring the capture of initial immune activation events.

450 To facilitate a more systematic and hierarchical interpretation of the cytokine atlas,  
451 we categorized these 120 plasma factors into four functionally distinct groups based on  
452 their well-characterized biological roles: pro-inflammatory mediators, anti-  
453 inflammatory mediators, chemokines, and growth factors. Subsequent comparative  
454 analysis between the A-infected group and normal group revealed a widespread and  
455 prominent elevation in the plasma levels of most of the profiled factors in infected  
456 individuals (**Fig 5a-e**). Specifically, 54 of these plasma factors met our predefined  
457 stringent significance criteria ( $FC > 2$  and  $p.adj < 0.05$ ) and were thus identified as  
458 significantly upregulated during the A-infection stage, reflecting a robust systemic  
459 immune activation (**Fig 5a**). We then extended our analysis to explore the expression  
460 patterns of these 120 plasma-related factors in our previously generated scRNA-seq  
461 dataset (**Fig 5f**). Applying the same stringent statistical criteria ( $FC > 2$  and  $p.adj <$   
462  $0.05$ ), we identified a notable overlap between the plasma proteomic and single-cell  
463 transcriptomic profiles: 14 genes were consistently differentially expressed in both  
464 datasets. Notably, these 14 co-differentially expressed genes included several key  
465 immune regulators with well-established roles in infection and inflammation: CXCL10,  
466 CCL8, CXCL11, CCL7, AXL, IL1RN, IL1B, CCL20, IGF1, FGF7, CSF1, LIF, CCL3,  
467 and TIMP1 (**Fig 5g**). Among these, multiple factors stand out for their conserved and

468 critical functions in viral infection: CXCL10 and CXCL11 (both the ligands of CXCR3)  
469 are potent chemoattractants for antiviral effector cells like T lymphocytes and NK cells,  
470 driving immune cell trafficking to infection foci<sup>40</sup>; CCL3, CCL7, and CCL8 recruit  
471 monocytes and neutrophils to amplify local innate immunity<sup>41</sup>; IL1B is a central pro-  
472 inflammatory cytokine that exacerbates antiviral immune responses and mediates  
473 infection-associated inflammation; and CSF1 promotes the differentiation and  
474 activation of macrophages-key cells for viral phagocytosis and antigen presentation<sup>42</sup>.  
475 Among these virus-relevant factors, CXCL10 emerges as the most prominently induced  
476 in our multi-omics data, warranting further exploration of its role and cellular source in  
477 acute viral infection (**Fig 5h**). Importantly, our scRNA-seq data further pinpointed that  
478 monocyte/pre-macrophage, two key myeloid precursor subsets identified in our earlier  
479 single-cell analysis represented the predominant cellular source of CXCL10 and other  
480 important cytokines (**Fig 5i**). This finding thereby establishes a clear cellular origin for  
481 the marked elevation of CXCL10 observed in the plasma of individuals with acute-  
482 stage infection. Previous studies have demonstrated that monocyte-derived  
483 macrophages migrate to the sites of infection in response to activation signals from  
484 chemokines such as CCL2 upon CHIKV induction<sup>43</sup>. Our findings, however, revealed  
485 that although CCL2 and its receptor CCR2 were both significantly highly expressed in  
486 monocytes, the pre-macrophages with high expression of both molecules accounted for  
487 a small proportion of the total population (**Fig S5a-b**). This may be attributed to the fact  
488 that pre-macrophages highly expressing CCL2 and CCR2 had migrated to the infection  
489 sites to exert their functional roles, whereas the blood-resident pre-macrophages with  
490 low expression of these two molecules were incompletely differentiated or undertake  
491 other critical biological functions. We further performed ELISA validation for plasma  
492 CXCL10 levels in CHIKV-infected patients, which revealed that plasma CXCL10  
493 expression was significantly elevated in all infected patients compared with the normal  
494 group (**Fig 5j**). CXCL10 functions as a key IFN-inducible chemokine that specifically  
495 binds to its cognate receptor CXCR3, thereby regulating the migration and activation  
496 of effector immune cells (e.g., T cells and NK cells) and acting as a central “immune

497 regulatory hub” in various RNA and DNA viral infections<sup>44</sup>. However, our results  
498 demonstrate that cell-cell communication between CXCL10-high expressing cells and  
499 other PBMCs is restricted to pDCs (**Fig 5k-l**), and the expression level of CXCR3 is  
500 low in almost all PBMC populations except pDCs (**Fig 5m**). This key phenomenon,  
501 which is inconsistent with previous studies, suggests that CXCL10 may not be critical  
502 in directly mediating immune cell migration during CHIKV infection. Instead, it may  
503 act on other untested cell types to exert other important functions. Or there may be  
504 undiscovered target receptors for CXCL10 in mediating immune cell migration, and  
505 the underlying mechanisms warrant further investigation. We then analyzed the  
506 transcription factors highly expressed in monocytes and pre-macrophages following  
507 CHIKV infection and identified several key transcription factors, including ATF3, IRF7,  
508 STAT1, STAT2 and others (**Fig S5c-d**). Furthermore, CXCL10 exhibited a moderate  
509 correlation in expression levels with the gene sets associated with these transcription  
510 factors (**Fig S5e-j**). WGCNA analysis revealed that the high expression of CXCL10 in  
511 Module 2 (**Fig S5k-m**) - an expression module highly correlated with pre-macrophages  
512 - was potentially associated with genes such as NFKBIZ, FCGR3A, CTSC and  
513 CDKN1C (**Fig 5n**).

514 In summary, during acute CHIKV infection, the potent and specific induction of  
515 CXCL10 may serve as a key chemotactic and signaling hub. Its prominent function in  
516 plasma cytokines suggests that CXCL10 could be used as a clinical biomarker.  
517 However, the key molecular mechanisms by which it coordinates innate and adaptive  
518 immune responses, or its role in promoting or inhibiting CHIKV replication, remain to  
519 be explored.

## 520 **Convalescence-dependent immune features and age-associated impairment**

521 CHIKV infection induces severe symptoms in patients during the acute phase and  
522 is often accompanied by persistent manifestations in the convalescent phase. Therefore,  
523 it is essential to investigate the immunological characteristics of distinct PBMC subsets  
524 and cytokines across different stages of CHIKV infection. Our results showed that  
525 compared with the acute infection phase, the proportions of various cell subsets in

526 convalescent patients underwent significant dynamic changes: pre-Macrophages and  
527 monocytes exhibited a trend of first increasing (acute phase) and then decreasing  
528 (convalescent phase), while NK cells and CD8<sup>+</sup> T cells displayed the opposite pattern  
529 of first decreasing and then increasing. Notably, naive CD4<sup>+</sup> T cells, naive CD8<sup>+</sup> T cells,  
530 and total CD4<sup>+</sup> T cells maintained a continuous upward trend throughout the infection  
531 course, which may indicate that pre-Macrophages, monocytes, NK cells, and CD8<sup>+</sup> T  
532 cells may dominate the immune response during the acute phase of CHIKV infection,  
533 whereas CD4<sup>+</sup> T cells mediate adaptive immune responses in the later post-infection  
534 stages (**Fig 6a-b & S6a**). The sustained elevation of naive CD4<sup>+</sup> and naive CD8<sup>+</sup> T cells  
535 is presumably driven by two main factors. First, CHIKV infection triggers the thymic  
536 emergency output of naive T cells, accelerating the differentiation and maturation of  
537 immature T cells that are subsequently massively released into the peripheral blood to  
538 replenish the immune pool. Second, it may result from the enhanced proliferative  
539 capacity of peripheral resting naive T cells. Additionally, compared with patients in the  
540 acute infection phase, those in the convalescent infection phase showed reduced acute  
541 inflammatory responses and interferon responses (**Fig 6c**), which suggests that the  
542 body's robust pro-inflammatory state gradually subsides in the convalescent phase, and  
543 the immune system transitions from an acute anti-viral defense mode to a state focused  
544 on restoring immune homeostasis.

545 Subclustering analysis of key cell subsets further revealed stage-specific features:  
546 for pre-Macrophages and monocytes, the proportions of major subclusters (C1, C2, C3)  
547 were restored to a near-normal state in the convalescent phase (**Fig 6d-e**), and  
548 terminally differentiated cells with high CXCL10 expression were also reduced  
549 compared with those in the acute phase of infection (**Fig 6f-g**). Consistently, CXCL10-  
550 whose expression is pivotal in the acute phase - was rapidly downregulated at this stage,  
551 further confirming its pivotal role in acute CHIKV infection (**Fig 6h**). Similarly, the  
552 expression levels of IL1RN and IL1B, which are highly upregulated in A-infection  
553 group, also decreased sharply in the convalescent phase (**Fig S6b**). For NK cells,  
554 although the proportion of subcluster C3 continued to increase from the acute to the

555 convalescent infection phase (in contrast to the decreasing trend of C2), the  
556 differentiation capacity of C1 and C2 subclusters was significantly restored in the  
557 convalescent phase (**Fig 6j-l**). For naive CD8<sup>+</sup> T cells and total CD8<sup>+</sup> T cells,  
558 subclustering analysis showed a slight increase in the proportion of subcluster C1 (naive  
559 CD8<sup>+</sup> T cells) in the convalescent infection phase, and except for subcluster C4, the  
560 proportions of other subclusters either continued to rise or fall, implying that CD8<sup>+</sup> T  
561 cell-mediated cellular immunity still plays an key function in the convalescent stage of  
562 infection (**Fig 6m-n**). Moreover, pseudotime analysis revealed that the proportion of  
563 CD8<sup>+</sup> T cells at the early pseudotime stage in the convalescent phase tends to approach  
564 an immune homeostasis state (**Fig 6o& S6c**). Additionally, subclustering analysis of  
565 CD4<sup>+</sup> T cell subsets showed that the proportion of naive CD4<sup>+</sup> T cells (Cluster 1)  
566 slightly increased during the acute infection phase but markedly increased in the  
567 convalescent phase (**Fig 6p-q & S6d**). Pseudotime analysis further revealed that the  
568 gene expression profiles of the massively increased naive CD4<sup>+</sup> T cells in the  
569 convalescent phase appeared to be in the late pseudotime stage (**Fig 6r-s & S6e**),  
570 indicating that these cells may be in a transitional state between naive and antiviral  
571 infection states and play an important role in antiviral immunity during the convalescent  
572 phase.

573 Notably, we also included an elderly patient in our analysis and found that in the  
574 acute infection phase, the elderly patient exhibited weaker acute immune responses and  
575 interferon responses compared with young patients (**Fig S6f**); furthermore, the  
576 expression levels of CXCL10, IL1RN, and IL1B - key immune factors that exert crucial  
577 anti-CHIKV effects - were significantly lower in the elderly patient than in young  
578 patients (**Fig S6g**). These findings suggest that the anti-infection immune response is  
579 relatively impaired in elderly patients, which may be a key factor contributing to  
580 potential differences in disease severity, clinical outcomes, or recovery rates between  
581 elderly and young populations infected with CHIKV.

582 These results investigated immunological characteristics of PBMC subsets and  
583 cytokines across CHIKV infection stages. Convalescent patients showed dynamic cell

584 proportion changes. Acute inflammatory/interferon responses subsided in  
585 convalescence, with restored subcluster proportions of key cells, downregulated  
586 CXCL10/IL1RN/IL1B, and recovered NK cell differentiation. Notably, elderly patients  
587 exhibited impaired immune and interferon responses with lower key factor expression.

### 588 **Phylogenetic analysis of Shenzhen strains and identification of marker genes for** 589 **viremia severity**

590 Previous studies have demonstrated a high degree of homology between the  
591 Foshan CHIKV strain and the Réunion CHIKV strain, suggesting that the endemic  
592 Foshan CHIKV strain may have originated from Réunion. However, it remains unclear  
593 whether the local outbreak in Shenzhen is associated with the Foshan outbreak or  
594 represents an independent imported event. To address this uncertainty, we extracted  
595 RNA from the serum of patients at different infection stages for next-generation  
596 sequencing (NGS) to perform viral genetic analysis, and simultaneously detected the  
597 abundance and types of host mRNA in serum as potential “auxiliary markers” for the  
598 severity of viremia. Among the 5 enrolled patients, complete viral sequences were  
599 detected in 2 cases (viremic patients) with an admission time of 3 days post-onset, while  
600 no complete viral sequences were identified in the other 3 cases (convalescent patients)  
601 whose admission time was 4-8 days post-onset (**Fig 7a**). These findings indicate that  
602 the time window of viremia following CHIKV infection occurs within 3 days post-  
603 onset. Notably, a substantial amount of host mRNA information was detected during  
604 the analysis of the viral genome in serum. To identify host serum markers indicative of  
605 viremia severity, we compared the serum mRNA profiles of the 2 viremic patients with  
606 those of the 3 convalescent patients (control group). The results showed that numerous  
607 host genes were highly expressed in the serum of infected patients, including *TAP1*,  
608 *ISG15*, *CMPK2*, *GBP4*, *OTOF*, and *SIGLEC1* (**Fig 7b**). Further analysis revealed a  
609 strong positive correlation between the expression levels (FPKM values) of these genes  
610 in serum and the viral gene content (FPKM values) (**Fig 7c**). We also validated the  
611 expression of these host genes in serum by qPCR, and the results similarly confirmed  
612 a high positive correlation between the expression of these host genes and viral gene

613 content (FPKM values) (**Fig 7d**). These data suggest that these host genes in serum can  
614 serve as “auxiliary markers” for the severity of viremia. Subsequently, we measured the  
615 mRNA levels of these genes in the serum of healthy volunteers. Compared with infected  
616 patients, the expression of these 6 genes was barely detectable in the serum of healthy  
617 volunteers, which further confirms the reliability of these genes as markers for the  
618 severity of CHIKV viremia (**Fig 7e**). Combined with single-cell sequencing data  
619 analysis, we found that genes with a strong correlation ( $R^2 \geq 0.98$ ), such as *TAP1*, *ISG15*,  
620 *CMPK2*, and *GBP4*, were highly expressed in almost all PBMCs and were closely  
621 associated with the activation of the interferon pathway. In contrast, genes with a  
622 relatively weak correlation ( $0.9 \leq R^2 < 0.98$ ) tended to be expressed in monocyte, pre-  
623 macrophage and cDC (**Fig 7f**). Specifically, *SIGLEC1* is involved in the activation-  
624 driven process of macrophages<sup>45</sup>, while *OTOF* is associated with calcium-dependent  
625 vesicle release<sup>46</sup>. Collectively, these results indicate that CHIKV infection elicits  
626 immune responses in almost all PBMC populations, and monocyte/pre-macrophages-  
627 related specific immune responses are also crucial. The aforementioned mRNAs can  
628 serve as “auxiliary markers” for the severity of viremia. We further performed IGV  
629 analysis to assess the integrity of these relevant genes in serum and found that all six  
630 genes had intact transcript structures (**Fig 7g & Fig S7a-d**). This implies that host  
631 mRNA in serum is more likely derived from active cellular efflux rather than  
632 fragmented gene leakage caused by cell death.

633 Phylogenetic tree analysis showed that the Shenzhen CHIKV strain shared high  
634 homology with the East/Central/South African (ECSA) lineage strain (MT666071.1)  
635 and belonged to the ECSA lineage (**Fig 7h**). This suggests that the endemic Shenzhen  
636 strain is most likely derived from imported cases rather than the previously sporadic  
637 strains circulating in China. Mutation analysis revealed that both the Shenzhen strain  
638 and MT666071.1 harbored the combined mutations of E1-A226V, E2-L210Q and E2-  
639 I211T, and these adaptive mutations enhance the transmission capacity of CHIKV. In  
640 addition, compared with MT666071.1, the Shenzhen strain also carried the C-T143A  
641 mutation (which enhances the transmission capacity of CHIKV in *Aedes aegypti*), the

642 E2-Q282 mutation, and the E1-R157K mutation (**Fig 7i**). Whether the latter two  
643 mutations can promote CHIKV transmission remains unclear. These genetic  
644 characteristics help explain the rapid spread of the outbreak. Notably, a large number  
645 of nucleotide and amino acid mutations were also detected between the two Shenzhen  
646 strains, of which two codon mutations caused amino acid changes (NSP1-I468V, NSP3-  
647 V189A) (**Fig 7j**).

648 In summary, the above study performed viral genetic analysis and plasma mRNA  
649 profiling to investigate the Shenzhen CHIKV outbreak and identify viremia-associated  
650 markers. Viral sequencing revealed viremia occurs within 3 days post-onset, and 6 host  
651 genes (e.g., TAP1, ISG15) in serum were validated as reliable auxiliary markers for  
652 viremia severity. Phylogenetic analysis showed the Shenzhen strain belongs to the  
653 ECSA lineage, likely imported rather than derived from domestic sporadic strains, and  
654 harbors multiple adaptive mutations (e.g., E1-A226V) enhancing transmission capacity,  
655 plus unique mutations. Notable genetic variations were also found between the two  
656 Shenzhen strains, indicating that CHIKV is undergoing rapid mutation during local  
657 transmission or that the two Shenzhen cases may originate from distinct infection  
658 sources.

## 659 **Discussion**

660 This study systematically delineates the immunopathological mechanisms and  
661 viral evolutionary characteristics of CHIKV infection through an integrated multi-  
662 omics approach, including scRNA-seq, plasma cytokine profiling, and NGS. By  
663 analyzing PBMCs and plasma samples from CHIKV-infected patients across different  
664 disease stages and age groups, we provide a comprehensive understanding of host-virus  
665 interactions, identify novel biomarkers, and clarify the genetic features of the  
666 circulating strain in Shenzhen (**Fig 8**).

667 A key novelty of this work is the first comprehensive single-cell transcriptomic  
668 atlas of PBMCs from CHIKV-infected patients, spanning acute and convalescent  
669 infection stages and including elderly individuals, revealing the dynamic perturbations

670 of immune cell subsets. Consistent with previous transcriptomic studies<sup>47,48</sup>, we  
671 observed robust activation of innate immune pathways, including IFN signaling and  
672 NF- $\kappa$ B-mediated pro-inflammatory responses. Monocytes and pre-macrophages are  
673 significantly expanded in the acute phase, serving as key sources of innate immunity  
674 and inflammatory mediators. Importantly, our single-cell data demonstrate that  
675 lymphopenia observed in blood routine blood tests (**Table 1**) is primarily attributed to  
676 the abnormal reduction of effector CD8<sup>+</sup> T cells (**Fig 4i**). Thus, we postulate that  
677 lymphopenia in CHIKV-infected patients is most likely caused by the massive  
678 infiltration of effector CD8<sup>+</sup> T cells into infected tissues, a phenomenon previously  
679 reported in the literature<sup>49</sup>. Naturally, we cannot rule out the possibility that CHIKV  
680 may induce effector CD8<sup>+</sup> T cell exhaustion and death, though no evidence has been  
681 found to support this possibility to date. Notably, we also found that the proportion of  
682 NK cell populations in CHIKV-infected patients is abnormally decreased, and their  
683 differentiation capacity, partial cytotoxic function, and NF- $\kappa$ B pathway are partially  
684 suppressed. This is inconsistent with previous studies reporting the specific expansion  
685 of NK cell subsets during acute CHIKV infection<sup>38</sup>. Further verification is needed to  
686 determine whether this phenomenon is associated with differences in viral strains. We  
687 also characterize the stage-specific immune remodeling: the acute phase is dominated  
688 by robust interferon and pro-inflammatory responses, while the convalescent phase  
689 features a transition toward immune homeostasis, with sustained elevation of naive  
690 CD4<sup>+</sup> T cells mediating long-term adaptive immunity<sup>50</sup>. Additionally, elderly patients  
691 show impaired immune activation and reduced expression of key factors (e.g., CXCL10,  
692 IL1RN), suggesting age-related vulnerability that may influence clinical outcomes.

693 Furthermore, our multi-omics analyses and experimental validation further  
694 confirm that CXCL10 is a key immune mediator of CHIKV infection. Both scRNA-  
695 seq and high-throughput plasma cytokine analyses demonstrate that CXCL10 is mainly  
696 secreted by monocytes and pre-macrophages, which is significantly upregulated during  
697 the acute phase of infection and transitions toward homeostasis in the convalescent  
698 phase. CXCL10 may exert a double-edged sword role in antiviral immunity: our data

699 show that CXCL10-high expressing cells exhibit enhanced antiviral pathways (e.g.,  
700 “defense response to virus”), while other studies have reported that CXCL10 signaling  
701 promotes the persistence of CHIKV<sup>51</sup> and HIV<sup>52</sup> in tissue-infiltrating macrophages.  
702 This discrepancy suggests that the function of CXCL10 is context-dependent (possibly  
703 associated with infection stage, cell type, or viral load), and further studies using in  
704 vitro and in vivo models are required to clarify whether it exerts a protective or  
705 pathogenic role.

706 In addition, NGS and plasma transcriptomic analyses identify six host mRNAs  
707 (TAP1, ISG15, CMPK2, GBP4, OTOF, SIGLEC1) as reliable auxiliary biomarkers for  
708 viremia severity, with intact transcripts indicating active cellular efflux rather than cell  
709 death-induced leakage. These biomarkers exhibit strong correlation with viral load and  
710 offer potential for early clinical diagnosis. Phylogenetic analysis further confirms that  
711 the Shenzhen CHIKV strain belongs to the ECSA lineage, harboring adaptive mutations  
712 (E1-A226V, E2-L210Q, E2-I211T) enhancing vector transmission and unique  
713 mutations (C-T143A, E1-R157K, E2-Q282K), providing insights into the outbreak’s  
714 origin and rapid spread.

715 Despite these insights, several limitations should be acknowledged. First, the  
716 definition of “acute” and “convalescent” stage relies solely on the onset of clinical  
717 symptoms (e.g., rash appearance), as precise infection timepoints could not be traced.  
718 Given CHIKV’s short incubation period<sup>53</sup>, viral replication may initiate days before  
719 symptom manifestation, which may lead to misclassification of disease stages and  
720 confound interpretations of immune cell dynamics. Second, our analysis of age-related  
721 immune responses is based on a single elderly patient. Although we observed weaker  
722 interferon responses and lower expression of key immune mediators (e.g., CXCL10,  
723 IL1RN, IL1B) in this individual compared to younger patients, this finding lacks  
724 statistical power and cannot be generalized to the broader elderly population. Larger  
725 cohorts of elderly patients are therefore needed to confirm age-related immune  
726 impairments and their potential impacts on disease severity and clinical outcomes.  
727 Third, the mechanism underlying the expansion of naive CD8<sup>+</sup> T cells remain elusive.

728 While our data indicate enhanced proliferative capacity of these cells, we cannot  
729 distinguish between two potential drivers: increased thymic emergency output of naive  
730 T cells or enhanced proliferation of peripheral resting naive T cells. Future studies  
731 should incorporate thymic function assays (e.g., T cell receptor excision circle [TREC]  
732 analysis) to clarify this ambiguity. Finally, the molecular basis for CHIKV-mediated  
733 suppression of NK cell differentiation remains unknown. Although viral proteins such  
734 as NSP3 have been shown to inhibit NF- $\kappa$ B signaling<sup>16</sup>, it remains unclear whether they  
735 directly target the differentiation pathways of NK cells or act indirectly via myeloid-  
736 derived suppressor factors - an area requiring further exploration.

737 Collectively, this study integrates scRNA-seq, plasma cytokine profiling and  
738 genomic data to unravel the complex immune networks and viral evolution during  
739 CHIKV infection. The findings advance our understanding of CHIKV  
740 immunopathogenesis, offer novel diagnostic biomarkers (e.g., plasma CXCL10 and  
741 host mRNAs), and identify potential therapeutic targets (e.g., CXCL10), laying a  
742 foundation for precision prevention and treatment of CHIKV infection.

## 743 **Materials and methods**

### 744 **1. Ethics approval and participant consent**

745 This research plan was approved by the Human Ethics Committee of The Third  
746 People's Hospital of Shenzhen and The Second Affiliated Hospital of Southern  
747 University of Science and Technology. The ethical number is No.2024-013-02.

### 748 **2. scRNA-seq Data Processing and Analysis**

#### 749 **2.1 scRNA-seq library construction and sequencing**

750 scRNA-seq libraries were constructed using the Single-Cell Full-Length RNA  
751 Transcriptome Sequencing Kit (Catalog No. K00801-08; SeekGene Co., Ltd., Beijing,  
752 China). Libraries were then sequenced on the Illumina NovaSeq 6000 platform  
753 (Illumina, Inc., San Diego, CA, USA) using paired-end sequencing with a 150 bp read  
754 length (PE150).

#### 755 **2.2 Processing and Quality Control of scRNA-seq Data**

756 Raw sequencing reads were processed through the Seeksoultools pipeline (v1.2.2)  
757 using default recommended parameters. FASTQ-formatted Illumina data were aligned  
758 to the GRCh38-2020-A reference genome with STAR (v2.7.10a). Following alignment,  
759 unique molecular identifiers (UMI) were counted and non-cell-associated barcodes  
760 were filtered out to construct a gene-barcode matrix for each sample, containing cell  
761 barcodes and corresponding gene expression counts. The resulting matrix was imported  
762 into the Seurat R package (v5.2.1) for quality control and downstream scRNA-seq  
763 analysis. Unless otherwise stated, all functions were executed with default parameters.  
764 Cells exhibiting a high proportion of mitochondrial genes expression or identified as  
765 doublets were filtered out. Quality control was carried out based on three standard  
766 metrics: the number of detected transcripts (UMI), the number of detected genes, and  
767 the percentage of reads mapped to mitochondrial genes (filtered using quartile-based  
768 thresholds). A subset of variable genes was then extracted from the normalized data,

769 with expression variability controlled relative to the mean using the NormalizeData  
770 function in Seurat.

### 771 **2.3 Cell Clustering and Annotation**

772 Graph-based clustering was performed on Principal Component Analysis (PCA)-  
773 reduced data using the shared nearest neighbor (SNN) graph and Louvain algorithm.  
774 For sub-clustering analyses, the same preprocessing pipeline-including scaling,  
775 dimensionality reduction, and clustering procedures-was applied to subset datasets,  
776 which were typically restricted to a single cell type. Seurat's FindClusters function was  
777 utilized for clustering of cell sub-clusters. Differential gene expression (DGE) analysis  
778 was conducted for each cluster using the Wilcoxon rank-sum test to identify  
779 significantly differentially expressed genes relative to all other clusters. Cell type  
780 annotation was performed using Single-Cell Integrative Annotation (SCINA), guided  
781 by established cell-type marker genes. Dimensionality reduction was performed using  
782 both PCA and uniform manifold approximation and projection (UMAP), facilitating  
783 data visualization and validation of clustering structures.

### 784 **2.4 Differential Expression Analysis and Functional Enrichment**

785 DGE analysis between healthy control and infected samples was performed at the  
786 single-cell level using Seurat's FindMarkers function. To identify cluster-enriched  
787 genes-genes with significantly higher expression in specific cell clusters relative to all  
788 other clusters-the following criteria were applied: (1) expressed in  $\geq 40\%$  of cells within  
789 the target cluster; (2) expressed in  $\leq 20\%$  of cells across all other clusters; (3) statistical  
790 significance (adjusted p-value  $\leq 0.05$ ); and (4) high expression change ( $\log_2FC \geq 0.5$ ).  
791 The top three genes per cluster, ranked by  $\log_2FC$  in descending order, were selected  
792 as cluster-specific marker genes. Dot plots illustrating marker gene expression across  
793 clusters were generated using Seurat's DotPlot function, with adjustments for  
794 visualization clarity (e.g., optimized gene labeling, dot size scaling). The same DotPlot  
795 function-with the split.by parameter (e.g., set to "sample group" for cohort distinction)-  
796 was further used to visualize key gene expression patterns across fresh samples within

797 each cluster. Additionally, Seurat's `AddModuleScore` function was employed to  
798 calculate enrichment scores for a predefined target gene set (e.g., infection-related  
799 pathways). Cells with high correlation to this gene set were identified using quartile-  
800 based thresholds.

## 801 **2.5 Pseudotime Analysis**

802 Pseudotime trajectory inference was performed using the `DDRTree` algorithm in  
803 `Monocle (v2.32.0)`. Log-normalized data from the Seurat object were imported into  
804 `Monocle`, and gene expression profiles were used to identify variable genes with cell-  
805 type-specific expression across cell groups and assess the statistical significance of  
806 these findings. Cells were ordered along the pseudotime trajectory and visualized in a  
807 reduced-dimensional space. To explore dynamic expression patterns, genes were  
808 grouped based on similar expression trends over pseudotime. Branch points in the  
809 trajectory were analyzed to identify genes associated with lineage divergence.  
810 Differential gene testing was applied to select genes significantly correlated with  
811 pseudotime progression or branch specification. Genes with significant branch-  
812 dependent expression were further visualized using the `plot_genes_branched_heatmap`  
813 function.

## 814 **2.6 Analysis of Cell-Cell Communication**

815 Intercellular communication networks among identified cell types were analyzed using  
816 the `CellChat R package (v2.1.2)`. For each experimental condition, a separate `CellChat`  
817 object was created and subsequently merged into a unified object via the `mergeCellChat`  
818 function. Interaction counts and communication strengths were evaluated using  
819 `compareInteractions`. Differences in the number and intensity of cellular interactions  
820 between the two datasets were visualized as a heatmap generated by `netVisual_heatmap`.  
821 Signaling pathway relatedness was quantified using the `rankSimilarity` function. The  
822 `netAnalysis_signalingRole_scatter` function was applied to identify significant changes  
823 in signaling sending and receiving roles across cell types. Specific alterations in  
824 signaling within selected cell populations were further investigated using

825 netAnalysis\_signalingChanges\_scatter. Finally, communication patterns of individual  
826 signaling pathways were compared across conditions using the netVisual\_aggregate  
827 function.

## 828 **2.7 Transcription Factor Regulon Analysis**

829 Transcription factor (TF) regulatory networks and regulon activities were characterized  
830 using the pySCENIC toolkit. Regulon activity was quantified as the area under the  
831 curve (AUC) value and evaluated with the AUCcell module. Active regulons were  
832 defined based on the module's default AUC threshold. Differential regulon activity  
833 across cell groups was assessed using the Wilcoxon rank-sum test via the  
834 FindAllMarkers function in Seurat, with the following settings: logfc.threshold =0.25,  
835 min.pct =0.1, pseudocount.use=FALSE, and only.pos =TRUE. Finally, a heatmap was  
836 generated to display the z-score scaled regulon activity across identified cell clusters.

## 837 **3. Plasma Sample Detection Using Human Cytokine Array Q2000**

838 Plasma levels of 120 cytokines were measured with the Human Cytokine Array  
839 QAH-CAA-2000 (RayBiotech). EDTA-anticoagulated plasma from Acute-infection  
840 and normal groups (n=3 each) was centrifuged, aliquoted, and stored at  $-80^{\circ}\text{C}$ . After  
841 thawing and clarification, samples were diluted 2-fold with kit diluent. Array chips were  
842 blocked, loaded with diluted plasma, and incubated overnight at  $4^{\circ}\text{C}$ . Following washes,  
843 detection antibody cocktail and Cy3-streptavidin were applied sequentially.  
844 Fluorescence was scanned (InnoScan 300, 532 nm) and analyte concentrations were  
845 derived from standard curves ( $R^2 \geq 0.95$ ; generated using serially diluted calibrators)  
846 using the manufacturer's software, with sample concentrations interpolated based on  
847 their fluorescence signals.

## 848 **4. Determination of plasm CXCL10 concentration using Dayou ELISA Kit**

849 CXCL10 concentration was determined using the Dayou precoated ELISA kit (Cat. No.  
850 1117452). Plasma samples were pretreated with anticoagulant, centrifuged, and the  
851 supernatant collected. All reagents were equilibrated to room temperature. A standard  
852 curve was prepared by serial dilution (200 - 3.13 pg/mL). After adding standards, blank,

853 and samples to the plate, incubation and washing steps were performed sequentially  
854 with biotinylated antibody and streptavidin-HRP. TMB substrate was added for color  
855 development, followed by stop solution. Absorbance was measured at 450 nm within  
856 10 min. Sample concentrations were interpolated from a four-parameter logistic (4-PL)  
857 standard curve ( $R^2 > 0.95$ ), and all assays were performed with three technical replicates  
858 across two independent experiments.

## 859 **5. RT-qPCR assay**

860 Total RNA was extracted from plasma samples with TRIzol™ LS Reagent (Invitrogen,  
861 #10296010CN), and cDNA was synthesized (Vazyme, #R232) following the  
862 manufacturers' protocols. Quantitative real-time PCR was performed with SYBR  
863 Green (Vazyme, #Q412) in a 20  $\mu$ L reaction volume. The cycling conditions comprised  
864 an initial denaturation step at 95 °C for 5 min, 45 cycles of 95 °C for 10 s and 60 °C for  
865 30 s, and a subsequent melting curve analysis. Specifically, the forward primer of TAP1  
866 was 5'-TGCCCCGCATATTCTCCCT-3' and the reverse primer was 5'-  
867 CACCTGCGTTTTGCTCTTG-3'; for ISG15, the forward primer was 5'-  
868 CGCAGATCACCCAGAAGATCG-3' and the reverse primer was 5'-  
869 TTCGTCGCATTTGTCCACCA-3'; for GBP4, the forward primer was 5'-  
870 ATGGGTGAGAGAACTCTTCACG-3' and the reverse primer was 5'-  
871 TGCGGTATAGCCCTACAATGG-3'; for CMPK2, the forward primer was 5'-  
872 GTACCTCCTTTATTCCTGAAGCC-3' and the reverse primer was 5'-  
873 ATGGCAACAACCTGGAACCTT-3'; for OTOF, the forward primer was 5'-  
874 CAACAAGCGTGTCGCCTATG -3' and the reverse primer was 5'-  
875 TCCTTGCGCTGTTTGCTGA-3'; for SIGLEC1, the forward primer was 5'-  
876 CCTCGGGGAGGAACATCCTT-3' and the reverse primer was 5'-  
877 AGGCGTACCCCATCCTTGA-3'.

## 878 **6. Evolutionary and mutational analyses**

879 For raw FASTQ-format sequencing data, we first aligned reads to the human rRNA  
880 database using Bowtie2 (v2.4.5) and removed the aligned reads. We then used fastp

881 (v0.23.2) to filter out low-quality reads according to three criteria, including adapter  
882 contamination, the presence of uncertain nucleotides (N) in excess of 10% within a  
883 single read, and low-quality nucleotides (quality value < 20) accounting for more than  
884 50% of a read. These high-quality reads were subsequently aligned to the human  
885 genome (GRCh38) via Bowtie2, while unaligned reads were aligned to the  
886 chikungunya virus genome (NC\_004162.2). The BAM files generated from these  
887 alignments were processed with featureCounts (v2.0.1) for gene quantification. For  
888 virus-aligned BAM files, consensus sequence assembly was performed using the  
889 samtools (v1.15.1) mpileup command, and base mutations were analyzed with the iVar  
890 variants command. Finally, phylogenetic relationships among multiple viral strains  
891 (NC\_004162.2, HM045816.1, HM045817.1, KP003809.1, MH229986.1, FJ445428.2,  
892 KX262989.1, JQ861258.1, MF076573.1, MH000703.1, MTO38402.1, HM045806.1,  
893 KX262990.1, MT591084.1, OK316994.1, KY435463.1, KR046234.1, MT666071.1,  
894 MT636912.1, Shenzhen/202507, Shenzhen/202508 ) were inferred using the Nextstrain  
895 bioinformatics pipeline. Briefly, genome sequences were aligned via MAFFT, and a  
896 maximum-likelihood phylogenetic tree was constructed using the tree module of Augur  
897 (v32.1.0). The resulting tree was further refined via temporal reconstruction and  
898 ancestral state inference with the Augur refine module, viral mutations were inferred  
899 using the Augur ancestral module, and the corresponding time-resolved phylogenetic  
900 tree was visualized with Auspice (<https://auspice.us>). After phylogenetic analysis with  
901 the Nextstrain pipeline, we selected MT666071.1 - the strain most closely related to our  
902 target CHIKV - as a new reference genome to enhance alignment accuracy. All  
903 sequencing reads were re-aligned to this optimized reference genome via Bowtie2, and  
904 subsequent variant calling was conducted using a custom pipeline integrating the  
905 samtools mpileup (v1.15.1) and iVar variants (v1.3.1) commands.

## 906 **Acknowledgements**

907 We gratefully acknowledge partial support for this work from the Biosafety Level III  
908 Laboratory and Biological Sample Bank of Shenzhen Third People's Hospital for bio-

909 samples and services, and the Center for Computational Science and Engineering at  
910 Southern University of Science and Technology. We thank all volunteers for their  
911 contributions to this research. The graphical abstract, Figure 1a and Figure 8 were  
912 created using BioRender (<https://BioRender.com>).

### 913 **Author contributions**

914 HY, ZY, RD, MZ, XL, JS and HL developed the concept of the project and wrote the  
915 paper. HY, ZY, SY and RD performed the experiments. XW, FO, XL, SH, YL, WL,  
916 TA, JY and XL analyzed the data with HY, HL and ZY. HY, MZ, TA, and HL  
917 supervised the project. All authors have read and agreed to the published version of the  
918 manuscript.

### 919 **Funding**

920 This work was supported by grants from the National Natural Science Foundation of  
921 China (No. 32300659); Shenzhen Science and Technology Innovation Commission  
922 Project (No. JCYJ20230807143302004); Shenzhen Clinical Research Center for  
923 Emerging Infectious Diseases (No. LCYSSQ20220823091203007); Guangdong  
924 Province Science and Technology Plan Project “Biosafety Technology” Special Project  
925 (No. 2022B111010003); Shenzhen High-level Hospital Construction Fund (No. XKJS-  
926 2025014, 23274G1001).

## 927 **References**

- 928 1 Bartholomeeusen, K. *et al.* Chikungunya fever. *Nat Rev Dis Primers* **9**, 17 (2023).  
929 <https://doi.org/10.1038/s41572-023-00429-2>
- 930 2 Ribeiro Dos Santos, G. *et al.* Global burden of chikungunya virus infections and the potential  
931 benefit of vaccination campaigns. *Nat Med* **31**, 2342-2349 (2025).  
932 <https://doi.org/10.1038/s41591-025-03703-w>
- 933 3 Wang, J. & Zhang, L. The chikungunya virus outbreak in Foshan, China: A rising public health  
934 threat in tropical and subtropical regions. *J Infect* **91**, 106591 (2025).  
935 <https://doi.org/10.1016/j.jinf.2025.106591>
- 936 4 Maure, C. *et al.* Chikungunya vaccine development, challenges, and pathway toward public  
937 health impact. *Vaccine* **42**, 126483 (2024). <https://doi.org/10.1016/j.vaccine.2024.126483>
- 938 5 Kolimenakis, A. *et al.* The role of urbanisation in the spread of Aedes mosquitoes and the  
939 diseases they transmit-A systematic review. *PLoS Negl Trop Dis* **15**, e0009631 (2021).  
940 <https://doi.org/10.1371/journal.pntd.0009631>
- 941 6 Tsetsarkin, K. A., Vanlandingham, D. L., McGee, C. E. & Higgs, S. A single mutation in  
942 chikungunya virus affects vector specificity and epidemic potential. *PLoS Pathog* **3**, e201 (2007).  
943 <https://doi.org/10.1371/journal.ppat.0030201>
- 944 7 Gloria-Soria, A. *et al.* Vector Competence of Aedes albopictus Populations from the  
945 Northeastern United States for Chikungunya, Dengue, and Zika Viruses. *Am J Trop Med Hyg*  
946 **104**, 1123-1130 (2020). <https://doi.org/10.4269/ajtmh.20-0874>
- 947 8 Ramphal, Y. *et al.* Understanding the Transmission Dynamics of the Chikungunya Virus in Africa.  
948 *Pathogens* **13** (2024). <https://doi.org/10.3390/pathogens13070605>
- 949 9 Tsetsarkin, K. A. & Weaver, S. C. Sequential adaptive mutations enhance efficient vector  
950 switching by Chikungunya virus and its epidemic emergence. *PLoS Pathog* **7**, e1002412 (2011).  
951 <https://doi.org/10.1371/journal.ppat.1002412>
- 952 10 Tsetsarkin, K. A. *et al.* Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya  
953 virus to Aedes albopictus and Ae. aegypti mosquitoes. *PLoS One* **4**, e6835 (2009).  
954 <https://doi.org/10.1371/journal.pone.0006835>
- 955 11 Paixao, E. S. *et al.* Chikungunya chronic disease: a systematic review and meta-analysis. *Trans*  
956 *R Soc Trop Med Hyg* **112**, 301-316 (2018). <https://doi.org/10.1093/trstmh/try063>
- 957 12 Ren, J., Ling, F., Liu, Y. & Sun, J. Chikungunya in Zhejiang Province, Southeast China. *Infect Med*  
958 *(Beijing)* **2**, 315-323 (2023). <https://doi.org/10.1016/j.imj.2023.11.005>
- 959 13 Goncalves, W. A., de Sousa, C. D. F., Teixeira, M. M. & Souza, D. G. A brief overview of  
960 chikungunya-related pain. *Eur J Pharmacol* **994**, 177322 (2025).  
961 <https://doi.org/10.1016/j.ejphar.2025.177322>
- 962 14 Mapalagamage, M., Weiskopf, D., Sette, A. & De Silva, A. D. Current Understanding of the Role  
963 of T Cells in Chikungunya, Dengue and Zika Infections. *Viruses* **14** (2022).  
964 <https://doi.org/10.3390/v14020242>
- 965 15 Valdes-Lopez, J. F. *et al.* Interleukin 27, like interferons, activates JAK-STAT signaling and  
966 promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya  
967 viruses replication in human macrophages. *Front Immunol* **15**, 1385473 (2024).  
968 <https://doi.org/10.3389/fimmu.2024.1385473>
- 969 16 Roberts, G. C., Stonehouse, N. J. & Harris, M. The Chikungunya Virus nsP3 Macro Domain

- 970 Inhibits Activation of the NF-kappaB Pathway. *Viruses* **17** (2025).  
971 <https://doi.org/10.3390/v17020191>
- 972 17 Venugopalan, A., Ghorpade, R. P. & Chopra, A. Cytokines in acute chikungunya. *PLoS One* **9**,  
973 e111305 (2014). <https://doi.org/10.1371/journal.pone.0111305>
- 974 18 Kelvin, A. A. *et al.* Inflammatory cytokine expression is associated with chikungunya virus  
975 resolution and symptom severity. *PLoS Negl Trop Dis* **5**, e1279 (2011).  
976 <https://doi.org/10.1371/journal.pntd.0001279>
- 977 19 Sharma, S. K. & Jain, S. Chikungunya: A rheumatologist's perspective. *Int J Rheum Dis* **21**, 584-  
978 601 (2018). <https://doi.org/10.1111/1756-185X.13273>
- 979 20 Xiao, K. *et al.* A pan-immune panorama of bacterial pneumonia revealed by a large-scale single-  
980 cell transcriptome atlas. *Signal Transduct Target Ther* **10**, 5 (2025).  
981 <https://doi.org/10.1038/s41392-024-02093-8>
- 982 21 Bian, Z. *et al.* Deciphering human macrophage development at single-cell resolution. *Nature*  
983 **582**, 571-576 (2020). <https://doi.org/10.1038/s41586-020-2316-7>
- 984 22 Guilliams, M., Thierry, G. R., Bonnardel, J. & Bajenoff, M. Establishment and Maintenance of  
985 the Macrophage Niche. *Immunity* **52**, 434-451 (2020).  
986 <https://doi.org/10.1016/j.immuni.2020.02.015>
- 987 23 Ziegler-Heitbrock, L. *et al.* Nomenclature of monocytes and dendritic cells in blood. *Blood* **116**,  
988 e74-80 (2010). <https://doi.org/10.1182/blood-2010-02-258558>
- 989 24 Schilte, C. *et al.* Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.  
990 *J Exp Med* **207**, 429-442 (2010). <https://doi.org/10.1084/jem.20090851>
- 991 25 Cook, L. E. *et al.* Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus  
992 Replication and Modulating Neutrophil-Mediated Inflammation. *J Virol* **94** (2019).  
993 <https://doi.org/10.1128/JVI.00841-19>
- 994 26 Raftery, N. & Stevenson, N. J. Advances in anti-viral immune defence: revealing the importance  
995 of the IFN JAK/STAT pathway. *Cell Mol Life Sci* **74**, 2525-2535 (2017).  
996 <https://doi.org/10.1007/s00018-017-2520-2>
- 997 27 Gardner, J. *et al.* Chikungunya virus arthritis in adult wild-type mice. *J Virol* **84**, 8021-8032  
998 (2010). <https://doi.org/10.1128/JVI.02603-09>
- 999 28 Blazquez-Moreno, A. *et al.* Transmembrane features governing Fc receptor CD16A assembly  
1000 with CD16A signaling adaptor molecules. *Proc Natl Acad Sci U S A* **114**, E5645-E5654 (2017).  
1001 <https://doi.org/10.1073/pnas.1706483114>
- 1002 29 Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A Major Regulator of Leukocyte Adhesion,  
1003 Migration and Signaling. *Front Immunol* **10**, 1068 (2019).  
1004 <https://doi.org/10.3389/fimmu.2019.01068>
- 1005 30 Dunlock, V. E. Tetraspanin CD53: an overlooked regulator of immune cell function. *Med*  
1006 *Microbiol Immunol* **209**, 545-552 (2020). <https://doi.org/10.1007/s00430-020-00677-z>
- 1007 31 Simmons, D. P. *et al.* SLAMF7 engagement superactivates macrophages in acute and chronic  
1008 inflammation. *Sci Immunol* **7**, eabf2846 (2022). <https://doi.org/10.1126/sciimmunol.abf2846>
- 1009 32 Wu, Y. *et al.* SLAMF7 regulates the inflammatory response in macrophages during  
1010 polymicrobial sepsis. *J Clin Invest* **133** (2023). <https://doi.org/10.1172/JCI150224>
- 1011 33 Digiacomo, G., Ziche, M., Dello Sbarba, P., Donnini, S. & Rovida, E. Prostaglandin E2  
1012 transactivates the colony-stimulating factor-1 receptor and synergizes with colony-stimulating  
1013 factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase

- 1014 ERK1/2. *FASEB J* **29**, 2545-2554 (2015). <https://doi.org/10.1096/fj.14-258939>
- 1015 34 Guma, M., Ronacher, L. M., Firestein, G. S., Karin, M. & Corr, M. JNK-1 deficiency limits  
1016 macrophage-mediated antigen-induced arthritis. *Arthritis Rheum* **63**, 1603-1612 (2011).  
1017 <https://doi.org/10.1002/art.30271>
- 1018 35 Sha, H., Zhang, D., Zhang, Y., Wen, Y. & Wang, Y. ATF3 promotes migration and M1/M2  
1019 polarization of macrophages by activating tenascin-C via Wnt/beta-catenin pathway. *Mol Med*  
1020 *Rep* **16**, 3641-3647 (2017). <https://doi.org/10.3892/mmr.2017.6992>
- 1021 36 Long, K. M. & Heise, M. T. Protective and Pathogenic Responses to Chikungunya Virus Infection.  
1022 *Curr Trop Med Rep* **2**, 13-21 (2015). <https://doi.org/10.1007/s40475-015-0037-z>
- 1023 37 Brandstadter, J. D. & Yang, Y. Natural killer cell responses to viral infection. *J Innate Immun* **3**,  
1024 274-279 (2011). <https://doi.org/10.1159/000324176>
- 1025 38 Petitdemange, C. *et al.* Unconventional repertoire profile is imprinted during acute  
1026 chikungunya infection for natural killer cells polarization toward cytotoxicity. *PLoS Pathog* **7**,  
1027 e1002268 (2011). <https://doi.org/10.1371/journal.ppat.1002268>
- 1028 39 Borgherini, G. *et al.* Outbreak of chikungunya on Reunion Island: early clinical and laboratory  
1029 features in 157 adult patients. *Clin Infect Dis* **44**, 1401-1407 (2007).  
1030 <https://doi.org/10.1086/517537>
- 1031 40 Karin, N. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and  
1032 Beyond. *Front Immunol* **11**, 976 (2020). <https://doi.org/10.3389/fimmu.2020.00976>
- 1033 41 Yan, Q. *et al.* CC chemokines Modulate Immune responses in Pulmonary Hypertension. *J Adv*  
1034 *Res* **63**, 171-186 (2024). <https://doi.org/10.1016/j.jare.2023.10.015>
- 1035 42 Adams, R. C., MacDonald, K. P. A. & Hill, G. R. The contribution of the monocyte-macrophage  
1036 lineage to immunotherapy outcomes. *Blood* **145**, 1010-1021 (2025).  
1037 <https://doi.org/10.1182/blood.2024025680>
- 1038 43 Rulli, N. E. *et al.* Protection from arthritis and myositis in a mouse model of acute chikungunya  
1039 virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. *J Infect Dis*  
1040 **204**, 1026-1030 (2011). <https://doi.org/10.1093/infdis/jir470>
- 1041 44 Elemam, N. M., Talaat, I. M. & Maghazachi, A. A. CXCL10 Chemokine: A Critical Player in RNA  
1042 and DNA Viral Infections. *Viruses* **14** (2022). <https://doi.org/10.3390/v14112445>
- 1043 45 Zheng, Q. *et al.* Siglec1 suppresses antiviral innate immune response by inducing TBK1  
1044 degradation via the ubiquitin ligase TRIM27. *Cell Res* **25**, 1121-1136 (2015).  
1045 <https://doi.org/10.1038/cr.2015.108>
- 1046 46 Michalski, N. *et al.* Otoferlin acts as a Ca(2+) sensor for vesicle fusion and vesicle pool  
1047 replenishment at auditory hair cell ribbon synapses. *Elife* **6** (2017).  
1048 <https://doi.org/10.7554/eLife.31013>
- 1049 47 Wilson, J. A. *et al.* RNA-Seq analysis of chikungunya virus infection and identification of  
1050 granzyme A as a major promoter of arthritic inflammation. *PLoS Pathog* **13**, e1006155 (2017).  
1051 <https://doi.org/10.1371/journal.ppat.1006155>
- 1052 48 Bae, S., Lee, J. Y. & Myoung, J. Chikungunya Virus nsP2 Impairs MDA5/RIG-I-Mediated Induction  
1053 of NF-kappaB Promoter Activation: A Potential Target for Virus-Specific Therapeutics. *J*  
1054 *Microbiol Biotechnol* **30**, 1801-1809 (2020). <https://doi.org/10.4014/jmb.2012.12005>
- 1055 49 Davenport, B. J. *et al.* Chikungunya Virus Evades Antiviral CD8(+) T Cell Responses To Establish  
1056 Persistent Infection in Joint-Associated Tissues. *J Virol* **94** (2020).  
1057 <https://doi.org/10.1128/JVI.02036-19>

- 1058 50 Wauquier, N. *et al.* The acute phase of Chikungunya virus infection in humans is associated  
1059 with strong innate immunity and T CD8 cell activation. *J Infect Dis* **204**, 115-123 (2011).  
1060 <https://doi.org/10.1093/infdis/jiq006>
- 1061 51 Lin, T. *et al.* CXCL10 Signaling Contributes to the Pathogenesis of Arthritogenic Alphaviruses.  
1062 *Viruses* **12** (2020). <https://doi.org/10.3390/v12111252>
- 1063 52 Lane, B. R. *et al.* The C-X-C chemokine IP-10 stimulates HIV-1 replication. *Virology* **307**, 122-134  
1064 (2003). [https://doi.org/10.1016/s0042-6822\(02\)00045-4](https://doi.org/10.1016/s0042-6822(02)00045-4)
- 1065 53 Zhao, T., Chen, T., Zhang, J., Li, C. & Qin, C. Chikungunya virus: Current situation and future  
1066 challenges. *Biosaf Health* **7**, 348-356 (2025). <https://doi.org/10.1016/j.bsheal.2025.10.001>
- 1067





Figure 1

1068

1069 **Figure 1. Identification of cell populations among the PBMCs by scRNA-seq.** a Schematic  
 1070 overview of the study design and experimental workflow. b t-SNE visualization of all PBMC-  
 1071 derived cells from all cohorts, annotated to 12 major cell types. c Expression levels of selected  
 1072 canonical cell markers in 12 major cell types, with the color and size of each point corresponding  
 1073 to the cellular expression fraction of the marker genes, respectively. d t-SNE projections illustrating  
 1074 the expression patterns of representative canonical marker genes for each cell type. In each panel,

1075 color intensity reflects the expression level of the indicated gene (darker shades = higher expression).



**Figure 2**

1076

1077

**Figure 2. Differential cellular clustering and molecular response profiling between CHIKV A-**

1078

**infection and normal cohorts. a** t-SNE visualization of cellular cluster composition in normal vs.

1079

A-infection groups. **b** Dual-panel bar chart depicting the abundance of distinct cell types: the left


1080

panel illustrates the proportional abundance of each cell cluster, while the right panel presents the

1081

corresponding absolute cell numbers. **c** Combined volcano plots identifying DEGs for each cell type

1082 (A-infection vs. normal), the top five ranked genes are listed for each cluster. **d** Hierarchical tree  
1083 plot of GO enrichment analysis for up-regulated DEGs. **e** Box plots illustrating expression patterns  
1084 of representative GO terms across all cell types (A-infection vs. normal). **f** (left) Violin plot  
1085 illustrating the activation levels of ISG-related genes across all cell types in A-infection versus  
1086 normal groups; (right) Receiver operating characteristic (ROC) curves, with corresponding AUC  
1087 values indicated, evaluating the diagnostic potential of ISG-related genes. **g-h** Heatmap showing  
1088 differences in intercellular signaling across distinct cell types between the A-infection group and the  
1089 normal group: (left) Differences in incoming signaling; (right) Differences in outgoing signaling.  
1090 Red indicates elevated signal intensity in the A-infection group compared with the normal group,  
1091 while blue indicates reduced signal intensity; deeper color represents greater magnitude of signal  
1092 change. Statistical significance was analyzed by Wilcoxon rank-sum test, ns = not significant,  
1093 \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 3**

**Figure 3. Dissection of cellular heterogeneity in monocyte and pre-macrophage lineage cells.**

**a** UMAP visualization of 6 subclusters (C1-C6) from monocyte and pre-macrophage populations, displayed for normal and A-infection groups separately. **b** Bubble plot of subcluster percentage composition in normal and A-infection groups. **c** UMAP plot showing the distribution of monocytes and pre-macrophages: monocytes (light blue) and pre-macrophages (dark blue). **d** Dot plot of highly expressed genes in each subclusters. **e** Violin plots of CXCL10 expression across subclusters. **f-g** GO enrichment showing the significantly enriched terms in CXCL10-highly expressed pre-macrophages and monocytes; **(f)** Significantly enriched biological processes in CXCL10-highly

1103 expressed pre-macrophages, **(g)** Significantly enriched biological processes in CXCL10-highly  
1104 expressed monocytes. **h** The root node selection for monocyte and pre-macrophage lineages of  
1105 pseudotime trajectory, dashed line represents the pseudotime trajectory. **i** Pseudotime trajectory plot  
1106 showing the developmental trajectory of subclusters, the dashed circle denotes the region where  
1107 Subcluster C3 is relatively concentrated. **j** Pseudotime trajectory plot showing the distribution of  
1108 CXCL10-highly expressed subclusters. **k** Heatmap showing genes highly expressed at the initial  
1109 and terminal stages of pseudotime development. blue = low, red = high expression.



**Figure 4**

1110

1111 **Figure 4. Subclustering and immunological characterization of NK cells and CD8<sup>+</sup> T cells. a**

1112 UMAP visualization of NK cells, colored by 3 distinct subclusters (C1-C3). **b** Proportional

1113 abundance of each NK cell subcluster in A-infection and normal groups. **c** Differentiation potential


1114 of the three NK subclusters as predicted by CytoTRACE analysis. **d** Significantly enriched GO

1115 terms in the C3 subcluster. **e** Pseudotime trajectory analysis reconstructing the developmental

1116 continuum of NK cells. **f** Pseudotime trajectory plot depicting fate divergence of NK subclusters in

1117 A-infection vs. normal groups. **g** Heatmap comparing gene expression patterns between two

1118 terminal cellular fates (Fate1 and Fate2). **h-i** Bar plots displaying the significantly enriched GO  
1119 terms associated with Fate1 (h) and Fate2 (i). **j** Expression dynamics of CD69 and GNLY along  
1120 reconstructed pseudotime in A-infection vs. normal NK cells. **k** UMAP visualization of CD8<sup>+</sup> T  
1121 cells, annotated by six distinct subclusters (C1-C6). **l** Stacked bar plot showing proportional changes  
1122 of each CD8<sup>+</sup> T cell subcluster in A-infection vs. normal groups. **m** Pseudotime trajectory analysis  
1123 reconstructing the developmental continuum of CD8<sup>+</sup> T cells. **n** Pseudotime trajectory plot depicting  
1124 fate divergence of CD8<sup>+</sup> T cell subclusters (C1-C6) in A-infection vs. normal groups. **o** Heatmap  
1125 showing genes highly expressed at the initial and terminal stages of pseudotime development. **p-q**  
1126 Bar plots displaying significantly enriched GO terms associated with Cluster 2 (**p**) and Cluster 1 (**q**)  
1127 in chart **o**.




**Figure 5**

1128

1129 **Figure 5. Integrated analysis of plasma cytokine array and scRNA-seq. a** Volcano plot showing  
 1130 differential expression analysis of 120 immune-related genes from plasma protein array data, with  
 1131 cutoff criteria of  $\log_2FC > 1$  and  $p < 0.05$ . Red dots: significantly upregulated immune factors in  
 1132 infected patients; blue dots: significantly downregulated ones; gray dots: no significant alteration.  
 1133 **b-e** Heatmaps displaying 120 plasma factors stratified into four functional categories: (**b**) pro-  
 1134 inflammatory cytokines, (**c**) anti-inflammatory cytokines, (**d**) chemokines, and (**e**) growth factors;  
 1135 color scale represents z-score-normalized expression. **f** Volcano plot showing the differential

1136 expression analysis of 120 immune factor-related gene transcripts from scRNA-seq data of all  
1137 PBMCs (A-infection vs. Normal,  $\log_2FC > 1$  and  $p < 0.05$ ). Red dots: significantly upregulated  
1138 immune factors in infected patients; blue dots: significantly downregulated ones; gray dots: no  
1139 significant alteration. **g** Venn diagram illustrating the 14-gene overlapping set between differentially  
1140 expressed proteins (plasma array) and transcripts (scRNA-seq), defined by  $\log_2FC > 1$  and  $p < 0.05$ .  
1141 **h** Bar plot showing the fold change of the top 10 upregulated overlapping genes between plasma  
1142 proteins and scRNA-seq transcripts. **i** Violin plot illustrating the expression patterns of key  
1143 cytokines from the 14 overlapping hits (CCL3, CCL8, CXCL10, IL1RN, IL1B, CXCL11) that were  
1144 significantly upregulated in monocytes and macrophages. **j** Bar plot of plasma CXCL10  
1145 concentration (pg/mL) in infected cohorts vs. Normal, quantified by Elisa. **k** Chord diagram of the  
1146 CXCL signaling pathway network, where segments denote distinct immune cell types and chords  
1147 indicate intercellular interactions. CXCL10-highly expressed monocytes and macrophages were  
1148 isolated. **l** Ligand-receptor interaction analysis of CXCL10-CXCR3, p-value denotes interaction  
1149 significance. **m** Violin plots depicting CXCR3 expression levels across distinct immune cell subsets  
1150 in Normal vs. A-infection cohorts. **n** WGCNA co-expression network of module M2, where red  
1151 nodes represent genes and red edges denote significant co-expression relationships. Statistical  
1152 significance was determined by the Wilcoxon rank-sum test: \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .



**Figure 6**

1153

1154 **Figure 6. Analysis of stage-specific immunokinetics in patients during the convalescent phase**

1155 **of CHIKV infection. a** t-SNE plot showing cellular cluster composition in Normal, A-infection,

1156 and C-infection groups. **b** Bubble plot illustrating percentage distribution of 12 immune cell types


1157 across three groups. **c** Box plots of transcriptional responses (acute inflammatory response, Type I

1158 and Type II interferon responses) across distinct cell types between A-infection and C-

1159 infection groups. **d** UMAP plot displaying subclustering of monocytes and pre-macrophages in the  
1160 C-infection group. **e** Bubble plot illustrating percentage distribution of monocyte and pre-  
1161 macrophage subpopulations across three groups. **f** Pseudotime trajectory plot depicting  
1162 differentiation dynamics of monocyte and pre-macrophage subpopulations in the C-infection group.  
1163 **g** Pseudotime trajectory plot illustrating CXCL10 expression dynamics across monocyte and pre-  
1164 macrophage subpopulations in the C-infection group. **h** Violin plot showing CXCL10 expression  
1165 levels in PBMSs from A-infection and C-infection groups. **i** Bar plot of plasma CXCL10  
1166 concentration (pg/mL) in A-infection vs. C-infection patients, quantified by ELISA. **j** UMAP plot  
1167 displaying subclustering of NK cells in the C-infection group. **k** Bubble plot illustrating percentage  
1168 distribution of NK cell subpopulations across Normal, A-infection, and C-infection groups; **l** Violin  
1169 plot depicting Potency relative score expression levels across NK cell subpopulations across three  
1170 groups. **m** UMAP plot displaying subclustering of CD8<sup>+</sup> T cells in the C-infection group. **n** Bubble  
1171 plot illustrating percentage distribution of CD8<sup>+</sup> T cell subpopulations across three groups. **o**  
1172 Pseudotime trajectory plot depicting differentiation dynamics of CD8<sup>+</sup> T cell subpopulations in the  
1173 C-infection group. **p** UMAP plots showing CD4<sup>+</sup> T cell distribution across three groups. **q** Bubble  
1174 plot illustrating percentage distribution of CD4<sup>+</sup> T cell subpopulations across three groups. **r**  
1175 Pseudotime trajectory plots showing differentiation dynamics of CD4<sup>+</sup> T cell subpopulations across  
1176 three groups. **s** Heatmap showing genes highly expressed at the initial and terminal stages of  
1177 pseudotime development (CD4<sup>+</sup>). Statistical significance was analyzed by Wilcoxon rank-sum test,  
1178 \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



1186 Correlation plot of qPCR relative quantification values of host mRNA and FPKM values of viral  
1187 genome in plasma. **e** qPCR results showing the relative expression levels of relevant mRNAs in  
1188 plasma from the normal group and infected group. The ID of the three infected patients: P1, P2, P3.  
1189 **f** Violin plot showing the TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1 expression levels in  
1190 PBMCs from A-infection and normal group. **g** IGV plot showing normalized read counts of GBP4  
1191 and TAP1 genes in plasma. **h** Radial plot of phylogenetic relationships between multiple strains.  
1192 AUL-Am: Asian Urban + American Lineage, AUL: Asian Urban Lineage, WA: Western African  
1193 Lineage, MAL: Middle African Lineage, IOL: Indian Ocean Lineage, SAL: South American  
1194 Lineage, EAL: Eastern African Lineage. **i** Shared amino acid mutations in the structural protein  
1195 regions between the two Shenzhen viral strains compared with MT666071.1. **j** Nucleotide and  
1196 amino acid mutations in the structural and non-structural protein regions between the two Shenzhen  
1197 CHIKV strains. AA: amino acid.



1198

1199

**Figure 8.** Summary of the experimental hierarchical design and key findings of the entire study.

1200 **Table 1. Characteristics and laboratory findings of healthy donors and enrolled patients**  
 1201 **infected with Chikungunya virus in the study.**

| Sample ID                               | Normal          |        |        | Infection |        |        |         |        |
|---|-----------------|--------|--------|-----------|--------|--------|---------|--------|
|   | N1              | N2     | N3     | P1        | P2     | P3     | P4      | P5     |
| Charateristics                          |                 |        |        |           |        |        |         |        |
| Age, years                              | 36              | 26     | 24     | 16        | 19     | 23     | 57      | 34     |
| Sex                                     | Male            | Female | Female | Female    | Male   | Female | Female  | Male   |
| Time <sup>#</sup>                       | N/A             | N/A    | N/A    | 3d/7d     | 3d     | 4d/6d  | 5d      | 8d     |
| Fever                                   | No              | No     | No     | Yes       | Yes    | Yes    | Yes     | Yes    |
| Rash                                    | No              | No     | No     | No        | Yes    | Yes    | Yes     | Yes    |
| Arthrodynia                             | No              | No     | No     | Yes       | No     | No     | No      | No     |
| Blood routine                           | Reference range |        |        |           |        |        |         |        |
| Leucocytes count, × 10 <sup>9</sup> /L  | 3.5-9.5         |        |        | 5.34      | 3.73   | 3.71   | 4.17    | 3.69   |
| Neutrophils count, × 10 <sup>9</sup> /L | 1.8-6.3         |        |        | 4.25      | 2.48   | 1.50 ↓ | 2.80    | 2.14   |
| Lymphocytes count, × 10 <sup>9</sup> /L | 1.1-3.2         |        |        | 0.53 ↓    | 0.75 ↓ | 0.78 ↓ | 0.81 ↓  | 1.06 ↓ |
| Platelets count, × 10 <sup>9</sup> /L   | 125-350         |        |        | 187       | 307    | 240    | 191     | 274    |
| Haemoglobin, g/L                        | 115-150         |        |        | 141       | 118    | 165 ↑  | 140     | 121    |
| Blood biochemistry                      | Reference range |        |        |           |        |        |         |        |
| Albumin, g/L                            | 40-55           |        |        | 43.9      | 45.2   | 47.1   | 48.9    | 45.7   |
| Alanine aminotransferase, U/L           | 0-40            |        |        | 19        | 7      | 10     | 33      | 11     |
| Aspartate aminotransferase, U/L         | 0-35            |        |        | 30        | 18     | 20     | 21      | 17     |
| Total bilirubin, μmol/L                 | 0-21            |        |        | 11.7      | 14.5   | 10.1   | 11.9    | 8.9    |
| C-reactive protein, mg/L                | 0-6             |        |        | 24.57 ↑   | 3.40   | 8.40 ↑ | 12.43 ↑ | 2.47   |
| Interleukin-6, pg/mL                    | 0-7             |        |        | 25.80 ↑   | 11.9 ↑ | 1.91   | 5.22    | N/D    |

1202 “#” refers to the interval from symptom onset to PBMCs collection. PBMCs from Patient 1 (P1)  
 1203 were collected at 3 and 7 days post symptom onset, while those from Patient 3 (P3) were collected  
 1204 at 4 and 6 days post symptom onset. N/A: Not applicable; N/D: Not detected.

1205 In this study, peripheral blood samples were collected from 8 volunteers for subsequent data analysis,  
 1206 including 3 healthy controls and 5 infected patients (2 of whom were sampled at two separate time  
 1207 points). The samples used for the experiments are as follows. Single-cell transcriptome sequencing  
 1208 was performed on PBMCs isolated from 3 healthy controls, the primary samples of infected  
 1209 individuals P1-P5, and the secondary sample of infected individual P1. CXCL10 levels were  
 1210 quantified via ELISA in 7 plasma samples from the 5 infected patients (including samples at  
 1211 different time points) and 3 plasma samples from healthy controls. Plasma sequencing was  
 1212 conducted using primary plasma samples of the 5 infected individuals. Data for cytokine and qPCR  
 1213 assays were obtained from the primary plasma samples of infected patients P1, P2 and P3.